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It is accepted that cancer progression is a multi-step process including multiple
genetic and epigenetic events. In this study, two sets of candidate genes in colon and
lung cancer tumourigenesis were studied. The first set comprised members of a
family of genes whose proteins are important in the recognition of the
methylation/epigenetic status of other genes. The second set were members of a
pathway that normally regulate tissue development but whose abnormal, epigenetic
loss of activity could lead to tissue dysregulation and tumourigenesis.
MBD3 and MBD2 are two members of the MBD family of proteins with a methyl-
CpG-binding domain (MBD) involved in transcriptional silencing of methylated
genes. Both genes are located in chromosomal regions that suffer loss of
heterozygosity in colon and lung cancers. By SSCP analysis and methylation
sensitive restriction followed by PCR, 2 mutations were found in 28 cell lines and in
no cases was there evidence of gene silencing by hypermethylation of putative
promoter regions. RT-PCR and northern hybridisation showed expression ofMBD3
in all cancer cell lines examined. The results indicate that neither MBD2 nor MBD3
are major targets of genetic and epigenetic alteration in colon and lung cancers.
The Hedgehog (Hh) pathway is a highly conserved signaling cascade involved in
many developmental processes. Mutations in elements of the pathway are associated
with congenital diseases and a number of neoplasms. In this study, two genes of this
pathway, SMO and GLI3 were investigated for expression and epigenetic alterations
in colon and lung cancers. In three cell lines expression of SMO was absent, the
putative SMO promoter was fully methylated and GLI3 was not expressed. Two
other cell lines had a methylated wild-type SMO allele and expressed mutant SMO,
and also did not express GLI3. The results indicate that SMO is silenced by CpG
island hypermethylation in colon and lung cancer cell lines, that GLI3 is also
silenced in colon and lung cancer cell lines by an as yet unrevealed mechanism and
that GLI3 is possibly regulated by SMO in a manner outside the normal sequence of
steps currently thought to comprise the Hh pathway.
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1. Overview of cancer genetics and epigenetics
1.1. Oncogenes
The concept that tumours derive from genetic alteration originated about a century
ago, when Broca discovered that many members of a family suffered from breast or
liver cancer, and he deduced that tumour development was caused by an inherited
abnormality (Broca, 1866). Since then his hypothesis has been supported by
accumulating evidence generated by familial, epidemiological and cytogenetic
studies. In 1911, a breakthrough study in the campaign to target a genetic basis for
cancer was reported by Rous (Rous, 1911). He found that cell-free filtrates of a
sarcoma, which had previously arisen in a chicken, could cause a sarcoma
reproducibly in chickens. Although Rous's observation strongly supported the idea
that cancer could be induced virally, it also suggested that cancer could be caused by
genetic materials. Since the oncogenic element of the Rous sarcoma virus was
identified in 1976 (Stehlin et al., 1976), it has been known that the oncogenicity of
the virus relied on v-src, a transduced and mutated copy of the c-src cellular proto-
oncogene. Also it has been confirmed that all of acutely transforming RNA tumour
viruses harbour oncogenes that actually have their counterparts as transduced cellular
genes (the proto-oncogenes). So far more than 50 different proto-oncogenes have
been identified through various experimental strategies. In general, proto-oncogenes
are involved in a variety of growth regulatory pathways, and their protein products
are distributed throughout all subcellular compartments. The oncogenic mutant
alleles present in cancers are activated by sustained gain-of-function alterations
resulting from point mutation, chromosomal rearrangement, or gene amplification of
the proto-oncogene sequences. In most cancers, mutations in proto-oncogenes are
somatic, although germline mutations exist in some cases. Oncogenes related to
colon and lung cancers will be discussed in those sections.
1.2.Tumour suppressor gene (TSG)
The assay to detect chromosome deletions has played a major role in the process of
identification and cloning of another class of cancer-associated genes, the tumour
suppressor gene (TSG). Contrary to the oncogenes which are activated by dominant
mutations and whose activity is to promote cell growth, tumour suppressor gene act
in the normal cell as negative controllers of cell growth and lack normal function in
tumour cells. In general, therefore, the mutations inactivating tumour suppressor
genes are of the recessive type requiring mutation of both alleles to have an effect,
which is proposed by Knudson's two-hit hypothsis (Knudson, 1971). A large number
of tumour suppressor genes have been hypothesised to exist. Thus far, about 30
tumour suppressor genes have been identified and definitively implicated in cancer
development. Like proto-oncogenes, the cellular functions of the tumour suppressor
genes appear to be diverse. The well-known example of tumour suppressor genes is
p53. The definition ofp53 as a tumour suppressor gene had experienced a dramatic
turnaround. Initial findings suggested that p53 functioned as an oncogene in some in
vitro experiments (Lane and Benchimol, 1990; Eliyahu et al., 1984; Jenkins et al.,
1984; Parada et al., 1984). The first evidence to suggest thatp53 might frequently be
inactivated in human cancers was obtained from studies demonstrating that
chromosome 17p LOH was common in a number of different tumours types,
including colorectal, bladder, breast and lung cancer (Fearon et al., 1987; Vogelstein
et al., 1988; Baker et al., 1989; Nigro et at., 1989; Takahashi et al., 1989). Analysis
of the sequence of the p53 alleles retained in cancers with 17p LOH demonstrated
that the remaining p53 allele was mutated in the vast majority of such cases.
Additional evidence that p53 functions as a tumour suppressor gene in human cancer
has been provided by gene transfer studies (Baker et al., 1990). Based on the types of
tumours in which p53 mutations have been found and the prevalence of p53
mutations in those tumour types, p53 is believed to be among the most frequently
mutated genes in human cancer. Although gross rearrangements of the p53 gene are
seen in some paediatric tumours like osteosarcoma and rhabdomyosarcoma and
splice mutations are seen in some cancers, the vast majority of the somatic mutations
in p53 are missense mutations leading to amino acid substitutions in the central
portion of the protein (Greenblatt et al., 1994). The p53 gene encodes a 53 kd nuclear
protein that acts as a transcription factor, blocks the cell cycle at late G1 (El-Deiry et
al., 1993; Harper et al., 1993; Hermeking et al., 1997) and also can trigger apoptosis
(Miyashita and Reed, 1995; Wu et al., 1997; Polyak et al., 1997; Moroni et al., 2001;
Robles et al., 2001). p53 has a role in maintaining the stability of the genome during
cellular stress from DNA damage, hypoxia and activated oncogenes(Wang et al.,
1995; Ford and Hanawalt, 1995). Subsequently, RB, PI6, APC, BRCAs, etc. came
into the category of tumour suppressor genes (Whyte et al., 1988; Serrano et al.,
1993; Groden et al., 1991; Hall et al., 1990; Wooster et al., 1995). Different
experimental approaches demonstrated that they are important players in different
subsets of tumours at different stages.
Generally speaking, there are two types of tumour suppressor gene: so called
'gatekeepers' and 'caretakers' (see figure 1). Gatekeeper genes act directly to
6
regulate cell proliferation and are rate limiting for tumourigenesis. Each cell type has
only a few gatekeepers, examples being ARC, p53 and RB. Caretaker genes, by
contrast, do not directly regulate proliferation but when their function is interrupted
lead to accelerate conversion of a normal cell to a neoplastic cell. Caretaker genes are
required for the maintenance of genome integrity. The existence of numerous so-
called chromosomal instability disorders, in which germ-line mutations in a caretaker
gene lead to both genome instability and a predisposition to cancer, attests to the
importance of these genes in suppressing neoplastic transformation. Well-studied
caretaker genes are ATM, BRCA1 andBRCA2.
A major group of caretaker genes, DNA mismatch repair genes, has been defined in
tumours in which an inherited mutated predisposing gene plays a significant role.
These tumours include cancers in patients suffering from hereditary nonpolyposis
colorectal cancer (HNPCC) syndromes. The genes implicated in these tumours have
been defined as mutator genes or genes involved in the DNA mismatch repair
process. Mutational inactivation of both copies of a DNA mismatch repair gene
results in a significant repair defect and progressive accumulation of mutations
throughout the genome that eventually may cause the activation of oncogenes and
the inactivation of other tumour suppressors. Five human DNA mismatch repair
genes have been identified that are involved in HNPCC. Mutational analysis of
MMR genes in HNPCC shows that defective hMSH2 and hMLHl are the major
cause of the disease accounting for more that 95% of the identified germline
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Figurel. One possible relationship of caretaker and gatekeeper
pathways.
Gatekeeper tumour suppressors are best defined by the fact that: first, their loss of
function is rate-limiting for a particular step in multi-stage tumourigenesis; second,
they act directly to prevent tumor growth, and third, restoring gatekeeper function to
tumor cells suppresses neoplasia. By contrast, caretaker tumor suppressor genes act
indirectly to suppress abnormal growth by ensuring the fidelity of the DNA code
through effective repair of DNA damage or prevention of genomic instability (such
as microsatellite or chromosome instability).
Figure 1. One possible relationship of caretaker
and gatekeeper pathways
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mutations, whereas mutation of hPMSl and hPMS2 in HNPCC account for less than
5% of total germline mutations (Vasen et al., 1991; Fishel et al., 1993; Leach et al.,
1993; Lindblom et al., 1993).
Mutations have been identified in tumour suppressor genes that are inherited and
predispose human to cancer. Recent evidence indicates that genomic imprinting, an
epigenetic form of gene regulation that results in uniparental gene expression, can
also function as a cancer predisposing event. Thus, cancer susceptibility is increased
by both inherited genetic and non-inherited epigenetic events. Consequently,
carcinogenic agents can not only induce cancer through the formation of genetic
mutations but also through epigenetic changes that result in the inappropriate
expression of imprinted proto-oncogenes and tumour suppressor genes. Tumour
suppressor genes related to colon and lung cancers will be discussed in those
sections.
1.3. Haploinsufficiency effect of tumour suppressor gene
Although Knudson's two-hit model can explain the inactivation of some tumour
suppressor genes, increasing evidence is changing our perspective of tumour
suppressor gene function and regulation. Some evidence suggests that the
haploinsufficiency effect of a tumour suppressor gene as well as LOH at a given
tumour suppressor gene locus possess the same significance in the process of
tumourigenesis induced by tumour suppressor gene inactivation. To date, there are
three avenues by which the haploinsufficiency of certain tumour suppressor genes
take their effect:
1) Haploid levels of a tumour suppressor gene product are insufficient to inhibit the
activity of critical downstream target proteins involved in stimulating growth. For
example, thep27IKIPl gene is haploinsufficient for tumourigenesis in the mouse and
this appears to be due directly to the effects of haploid p27 protein levels because
expression from the wild-type p27 allele appeared normal (Fero et al., 1998). p27 is
one of the inhibitors of activity of cyclin/cdk complexes. Consequently, reduced
levels of p27 would be expected to increase cyclin/cdk activity and promote
tumourigenesis. Pten is another case of haploinsufficiency (Cristofano et al., 1999).
2) The tumour suppressor mutation acts in a dominant-negative fashion to block the
activity of wildtype tumour suppressor protein. Analysis of tumour formation in p53
heterozygous mice showed that only -50% of tumours show LOH at the p53 locus
(Venkatachalam et al., 1998), suggesting that mutant p53 allele may drive
tumourigenesis by dominant-negative fashion.
3) Expression from the wild-type allele is shut off/reduced as a result of epigenetics
events. Shoemaker et al. have shown that expression from the wild-type APC allele
is reduced in heterozygous tumours, suggesting that LOH equivalent effect is
achieved not by gene loss/mutation but by silencing APC gene expression from the
wild-type allele in an alternative manner similar to genomic imprinting (Shoemaker
et al., 1998).
1.3.Epigenetic gene silencing in cancer
1.3.1. CpG island and DNA methylation
CpG islands are GC-rich regions of DNA, stretching for an average of about 1 kb,
which are coincident with the promoters of -60% of human RNA polymerase II-
transcribed genes, e.g. so called housekeeping genes (Bird, 1986). Methylation of the
C5 position of 5' -CpG-3' dinucleotides of mammalian DNA is known to be a
powerful mechanism for the suppression of gene activity. DNA methylation within
some CpG islands is essential for human development, X-chromosome inactivation
and genomic imprinting (Jaenisch, 1997). DNA methylation may also suppress
transcriptional noise, defend the genome against retroviral elements, immobilise
transposons and control tissue-specific gene expression.
CpG sites occur less frequently than expected in mammalian DNA (~1 per 100
bases) and are usually methylated, but are clustered at a higher frequency (~lper 10
bases) in CpG islands where they are typically found unmethylated (Bird et al.,
1985). The regulatory influences of CpG sequences may be most important when
located in the 5' promoter regions of genes, however some intron and 3' methylation
influences have also been reported. In contrast to the unmethylated CpG islands of
all active housekeeping genes throughout the genome, the CpG islands of many
genes on the inactive X chromosome are methylated, as are the CpG islands ofmany
non-essential genes in long term cultured cells. The methylation status of a gene is
usually inversely correlated with gene expression, such that hypermethylation of
certain gene promoters yields gene inactivation and hypomethylation of these
promoters activates or reactivates gene expression. Aberrant methylation of CpG
islands in the promoter of many cancer-related genes results in silencing of their
expression (discussed later).
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1.3.2. The methylation machinery
It is thought that cellular DNA methylation patterns are established and maintained
by a complex interplay of at least three independent DNA methyltransferases:
DNMT1, DNMT3A and DNMT3B. DNMT1 was the first methyltransferase to be
identified and characterized (Bestor et.al., 1988). It is the most abundant
methyltransferase in somatic cells, localises to replication foci and interacts with the
proliferating cell nuclear antigen (Robertson et al., 1999; Leonhardt et al., 1992;
Chuang et al., 1997). It is often referred to as the maintenance methyltransferase
because it is believed to be the enzyme responsible for copying methylation patterns
after DNA replication. However, new evidences suggest that it can also act as a de
novo methyltransferase. DNMT1 is required for proper embryonic development,
imprinting and X-inactivation (Li et al., 1992; Li et al., 1993; Beard et al., 1995).
Subsequently the DNMT3 family of methyltransferases from mouse and human have
been characterized. They are thought to be the main de novo methyltransferase
activity in cells (Okano et al., 1998). Dnmt3a knockout mice are born live but die at
about four weeks of age. In contrast, Dnmt3b knockout mice are not viable (Li et al.,
1992; Okano et al., 1999).
1.3.3. DNA methylation and cancer
In cancer, two different DNA methylation events happen. Hypomethylation of the
wide genome occurs (Goelz et al., 1985), while increased localised methylation of
promoter-associated CpG islands is concurrently observed leading to silencing of
genes with normal tumour-suppressive activity (Jones and Laird, 1999) (see figure
2).
Figure 2. CpG island hypermethylation is associated with gene
silencing in cancer cell
Black circle represents methylated CpG sites while white circle represents
unmethylated CpG sites. A. In normal cells, CpG islands around or upstream of the
translation start are usually methylation-free while non-clustering CpG sites are
usually methylated. B. In cancer cells, such CpG are often methylated while






Figure 2. DNA liypermethylation is associated with
gene silencing in cancer cell
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A growing number of cancer genes are being recognised that suffer from
hypermethylation in normally unmethylated promoter CpG islands. Whether DNA
methylation initiates gene silencing or methylation is a secondary event following
gene silencing has yet to be resolved. But DNA methylation both marks and plays a
key role in an epigenetically mediated loss-of-gene function that is as critical and
frequent in tumourigenesis as mutations in coding regions. An excellent example is
the gene encoding the cyclin-dependent kinase inhibitor, pi6. The loss of pi6 occurs
through the different mechanisms of deletions, point mutation or promoter
hypermethylation. The frequency of each mechanism varies with different tumour
types. In certain tumours, like colon cancer, pi6 inactivation is seen only in
association with promoter hypermethylation (Kamb et al., 1994; Herman et al.,
1995). The incidence of functional disruption of pi6, especially when promoter
hypermethylation is included, indicates that this gene is as frequently inactivated as
p53 in cancer (Baylin, 1998). In addition to well-defined mutation of tumour-
suppressor genes, promoter hypermethylation is being associated with an increasing
list of other genes that have strongly been implicated in tumour development.
The demethylation happens mainly at transposable elements leading to aberrant
expression (Cohen and Shapiro, 1980; Craig, 1990; Hartl, 1997; Moffat, 2000). This
increased expression has the potential to cause mutational events through
transposition. Demethylation may also contribute to genomic instability. For
example, embryonic stem cells lacking DNMT1 display both a globally
hypomethylated genome and a higher degree of genetic instability (Chen et al.,
1998). In addition, pericentromeric areas which are normally heavily methylated
exhibit increased levels of chromosomal translocations when demethylated by a
demethylating substance (5-aza-dC)(Ji et al., 1997).
1.4.4.MBD and cancer
1.4.4.1. Methyl-CpG-binding proteins (MBDs)
The mechanism by which DNA binding proteins transduce the signal encoded by a
particular pattern of methylation to regulate gene expression has been studied for
over 30 years. In the early 1990s, two complexes with ability to bind to methylated
DNA were found, namely MeCPl and MeCP2. MeCP2 was the first true member of
the family of proteins that selectively recognise methylated CpG (Lewis et al., 1992;
Meehan et al., 1989). Bird and colleagues characterised the minimal region of
MeCP2 required for binding to methylated DNA, defining the so-called methyl-CpG-
binding domain (MBD)(Hendrich and Bird, 1998). MBD is a short region of MeCP2
containing about 70 residues located within its N-terminal that has the ability to bind
selectively methylated DNA. By database search for sequence homologous to the
MBD, Bird's group identified a protein containing a MBD-like motiflocated at its N-
terminus. This protein was named MBD1. MBD1 was shown to bind methylated
DNA and to repress transcription from a methylated promoter in vitro. It was initially
believed to be a component of the MeCPl complex (Cross et al., 1997). A further
search of EST databases found three more genes in mammalian cells that encode
proteins containing MBDs, namely MBD2, MBD3 and MBD4. Alignment of the
MBD-like regions from the murine MBD1 to MBD4 and MeCP2 proteins showed
that two subgroups could be established. The MBD of MBD4 is most similar to that
of MeCP2 in primary sequence, while the MBDs of MBD1, MBD2 and MBD3 are
more similar to each other than to those of either MBD4 or MeCP2. The sequence
similarity between these five proteins is largely limited to their MBD although
MBD2 and MBD3 share greater homology along their whole length (~70%).
Analysis ofMBD genes expression in numerous murine tissues showed that they are
expressed in all samples tested but embryonic stem cells, where DNA methylation is
known to be dispensable, seem to have low levels of mbdl and mbd2 transcripts
(Hendrich and Bird, 1998).
1.4.4.2. MBD3
MBD3 shares about 70% of overall identity with MBD2 over most of their length.
The greatest divergence occurs at the C-terminus, where MBD3 has 12 consecutive
glutamic acid residues encoded by an imperfect trinucleotide repeat. This
characteristic is retained in the human MBD3. MBD3 also has variants produced by
alternative splicing. Recently, two MBD3 like genes, MBD3L1 and MBD3L2 were
cloned and identified. The MBD3L1 is 42% identical to MBD3 and 38% identical to
MBD2 but lacks the methyl-CpG binding domain. The MBD3L1 gene is expressed
specifically in testis, suggesting a role in the development of male germ cells.
Interestingly, expression of MBD3L2 was found in germ cell tumours and some
somatic tissues (Jiang et al., 2002).
The most abundant is a 32-kDa protein that shares high homology to MBD2b (80%
similar, 72% identical). The second variant contains an insertion of a small exon (20
amino acids) in the MBD, with the rest of its sequence being identical with that of the
short form ofMBD3. These two MBD3 variants have been detected inhuman, mouse
and Xenopus systems. The recombinant MBD3 protein does not bind to methylated
DNA in vitro. Considering its high similarity to MBD2b, demethylase activity
(controversially reported for MBD2b) has also been tested for MBD3, however no
demethylase activity was detected (Hendrich and Bird, 1998).
MBD3 is one member of the NuRD complex, which is a multisubunit complex
containing nucleosome remodelling and histone deacetylase activities (Wade et al.,
1999, Zhang et al., 1999; Wade et al., 1998). One study indicates that Drosophila
gene dMBD2/3 forms specialised nuclear compartments to keep certain genes
epigenetically silenced during genome activation (Marhold et al., 2002). One group
hypothesised that the MBD2-MBD3 complex recognises hemi-methylated DNA
concurrent with DNA replication and recruits histone deacetylase complexes, as well
as DNMT1, to establish and/or maintain the transcriptionally repressed chromatin
(Tatematsu et al., 2000). Closely related proteins MBD2 and MBD3 play distinctive
but interacting roles in mouse development (Hendrich et al., 2001). MBD3, MeCP2
and MBD1 are also involving in imprinting selection (Fournier et al., 2002).
MBD3 is located on chromosome 19p 13.3, a region reported to suffer 20-50% LOH
in sporadic colorectal carcinomas (Resta et al., 1998; Trojan et al., 2000; Dong et al.,
1998). According to data compiled by the Human Genome Mapping Project
(available on the website http://www.ncbi.nlm.nih.gov/) MBD3 is within about
500kb of the gene LKB1/STK11 which is mutated or abnormally methylated in
Peutz-Jeghers syndrome. Peutz-Jeghers patients have hamartomatous polyposis of
the gastrointestinal tract and an increased risk of a range of cancers including colon.
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LKB1 is rarely mutated or methylated (maximum about 20%) however in sporadic
colorectal carcinomas (Resta et al., 1998; Trojan et al., 2000; Avizienyte et al., 1998;
Esteller et al., 2000; Launonen et al., 2000), raising the possibility that another gene
in the vicinity is involved in these cancers. The short arm of chromosome 19 is also
implicated in up to 86% of lung cancers (Lukeis et al., 1990; Virmani et al., 1998;
Sanchez-Cespedes et al., 2001). In the light of the location ofMBD3 in a region of
chromosomal loss, its known functions in transcription suppression - and data
connecting other MBD family members with cancer it was considered as a candidate
tumour suppressor gene.
1.4.4.3. MBD2
MBD2 is highly similar to MBD3 in a large region corresponding roughly to amino
acids 140-400 (Hendrich and Bird, 1998). This region of MBD2 contains a repeat
consisting of glycine and arginine residues (Hendrich and Bird, 1998). Compared to
MBD3, MBD2 has a more restricted pattern of expression and an alternatively
spliced mRNA is evident in testis (Hendrich and Bird, 1998). MBD2 binds
methylated DNA in a way similar to MeCP2 (Hendrich and Bird, 1998; Wade et al.,
1999). Surprisingly, MBD2b (a version lacking the amino terminal 140 amino acids)
has been reported to possess DNA demethylase activity (Bhattacharya et al., 1999),
although this finding has been questioned (Wade et al., 1999; Ng et al., 1999).
Immunoprecipitation studies demonstrate that MBD2 is physically associated with
HDAC1 in mammalian cells and implicate MBD2 as the methyl CpG binding
component of the MeCPl complex (Ng et al., 1999). While MBD2 is associated with
HDAC1 and with RbA p48/p46, coimmunoprecipitation analysis showed that it is
not a component of the previously defined Sin3 and Mi-2/NURD complexes (Ng et
al., 2000). However, a direct interaction of Sin3A with MBD2b in the region
sufficient to direct transcriptional repression has also been observed (Boeke et al.,
2000).
Whether MBD2 plays a role in cancer is attracting increasing attention. Our group
screened MBD2 by SSCP but failed to find enough mutations to suggest that MBD2
suffers from genetic alterations as a tumour suppressor gene. Although two groups
reported that the unregulated expression might be related to cancer progress (Billard
et al., 2002; Slack et al., 2002), the finding still needs further study to confirm and
elucidate.
1.4.4.4. MBD1, MBD4 and MeCP2 and their links to cancer
MBD1 is the largest member of the family and contains a sequence motif, the CXXC
motif, shared with DNA methyltransferase I (Cross et al., 1997). One group observed
that, in BPH (benign prostatic hyperplasia) tissues and low-grade cancer tissues,
MBD1 protein expression was very high and gradually decreased with increase of
cancer grade (Patra et al., 2003). However, our group screened colon and lung cancer
cell lines and primary tumours by SSCP and only found a small number of mutations
in the coding region of MBD1 (Bader et al., 2003). Thus, up to now, no strong
evidence has suggested that MBD1 is crucial for tumour pathogenesis.
A link between MBD4 and the MMR system was provided by the observation that
between 20% and 43% of primary human colorectal carcinomas that displayed
microsatellite instability (MSI) also harbored inactivating mutations in MBD4
(Riccio et al., 1999, Bader et al., 1999; Miyaki et al., 2001). In addition, MBD4
mutations were also frequently observed in other microsatellite unstable cancers such
as gastric, endometrial, and pancreatic carcinomas (Riccio et al., 1999; Yamada et
al., 2002). However, the failure to detect MBD4 mutations in microsatellite stable
tumours together with the lack of mutations occurring outside this mononucleotide
repeat track suggested that MBD4 mutations were likely the result, rather than the
cause, ofMMR deficiency (Bader et al., 1999).
The methyl CpG binding protein 2 gene, MECP2, encodes a global transcriptional
silencer and was identified as the gene defective in RTT (Rett syndrome, a
neurodevelopmental disorder that mostly affects females) (Amir et al., 1999).
Mutations in MECP2 so far identified in association with RTT are thought to cause
loss of function of the protein and therefore a generalised derepression of
transcription. Many other groups have undertaken mutation analysis, using a variety
of molecular techniques. Mutation detection in classically affected females varies
from 46% to 80% (Cheadle et al., 2000; Amano et al., 2000; Bienvenu et al., 2000).
So far, no substantial evidence has been found that MeCP2 is linked to
tumourigenesis.
1.5. Developmental gene regulation-hedgehog pathway
1.5.1. General introduction
The Hh gene was first identified as one of the many players that are required for
segmentation of the Drosophila embryo (Niislein-Volhard and Wieschaus, 1994).
We now know that it is also involved in numerous other aspects of embryonic, larval
and adult development in the fly and that it has homologs that play key roles in
human, mouse, frog, fish and chick development. The Hh proteins are secreted and
are thought to function as morphogens, signals that elicit concentration-dependent
responses from target cells. Increasing evidence show that Hedgehog (Hh) signalling
is a universal pathway that specifies and regulates the growth and differentiation of
organ systems in eukaryotes. It is crucial in patterning a diverse range of vertebrate
structures and organs during embryo development (Ingham and McMahon, 2001).
In contrast with Drosophila, which has only one hedgehog gene, three vertebrate
homologues have been identified, Sonic (Shh), Desert (Dhh), and Indian hedgehog
(Ihh). In vitro studies show that each of these proteins can act via the same signal
transduction pathway and that the different hedgehog genes regulate patterning of
different organ systems by their unique expression pattern. The most extensively
studied vertebrate hedgehog gene is Shh that is expressed widely in the developing
CNS, limb, lung, gut, teeth and hair-follicle. Dhh and Ihh are found mainly involved
in development of the germline and skeletal system respectively. (Ingham, 1998;
Goodrich and Scott, 1998; Muenke and Beachy, 2001; McMahon, 2000).
1.5.2. The mechanism of hedgehog signalling
Studies in vertebrate systems have built up a model for hedgehog signalling (see
figure 3). Hedgehog signals are received at the cell surface by a complex consisting
of the patched and smoothened proteins. According to this model, patched, a 12-pass
transmembrane protein is the ligand-binding component of the receptor complex.
Smoothened, a protein with homology to a serpentine G-protein coupled receptor, is
responsible for transducing the hedgehog signal. In the absence of hedgehog binding,
patched is thought to hold smoothened in an inactive state and thus inhibit signalling
to downstream genes. With the binding of hedgehog, patched inhibition of
smoothened is released and SMO then transduces a signal. A downstream complex
composed of fused, suppressor of fused, costal 2 and ci dissociates, and an active
form of ci translocates to the nucleus where it switches on transcription of the target
genes, wingless (homologous to the vertebrate Wnt genes), decapentaplegic (a
member of the superfamily most homologous to the vertebrate bone morphogenetic
proteins (Bmps), as well as patched itself (Saldanha, 2001).
So far, it is known that the Hh signal regulates target genes by two ways. One is to
activate Gli proteins to induce gene transcription and the other is to inhibit the
formation of Gli repressors (mostly those of Gli3) to derepress targets. Specifically,
Hh signaling induces Glil transcription and thus GUI acts as an activator to amplify
the Hh response. However, Gli2 and Gli3 functions are more complex than the role
of Glil, and possibly Gli3 can be variable in relation to Hh signaling in different
situations. Hh signaling represses both the transcription of Gli3 and the proteolytic
formation of Gli3 repressors. Hh signaling turns full-length Gli2 into a potent
activator. Besides, both Gli2 and GU3 could be involved in other signaling pathways,
as they are often expressed independent of Hh signalling (Matise and Joyner, 1999).
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Figure 3. Elements of hedgehog pathway conserved from Drosophila
to vertebrates
Hedgehog binds to patched releasing smoothened to transduce a signal. A
downstream complex composed of fused, suppressor of fused, costal 2 and ci
dissociates, and an active form of ci translocates to the nucleus where it switches on
transcription of the target genes, wingless, decapentaplegic and patched. PKA,




Aptc (PTCH, PTCHZ, TCR8)
Nucleus.
—► Stimulate —| Inhibit
Figure 3. Elements of hedgehog pathway
conserved from Drosophila to
vertebrates (human gene families
in parentheses).
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1.5.3. The role of Hh in animal development
Different roles have been described for Shh during development, acting as a
morphogen, mitogen or differentiation factor (Altaba et al., 2003). Hedgehog is also
important for development of the gut in Drosophila larvae. Shh is required for the
development of small intestine (Zhang et al., 2001) and for larval to adult intestine
remodelling in Xenopus (Ishizuya-Oka, 2001). In the chick, Shh is involved in
establishing the anterior/posterior and radial axis of the gut (Roberts et al., 1998 and
Sukegawa et al., 2000). Shh knockout mice have been reported to show foregut,
trachea and lung abnormalities (Litingtung et al., 1998), reduction of intestinal
smooth muscle, gut malrotation and annular pancreas (Ramahlo-Santos et al., 2000)
and persistent cloaca, where the distal intestinal and genitourinary tracts remain in a
common channel.
1.5.4. Hedgehog pathway and cancer
Since Glil was first identified as an amplified gene in a human glioblastoma, it has
also been found that several key components of the hedgehog pathway have been
implicated in tumour formation.
1.5.4.1 PTCH and cancer
It was the study that showed patched is mutated in both familial (NBCC, nevoid
basal cell carcinoma syndrome or Gorlin's syndrome) and sporadic forms (BCC) of
basal cell carcinoma that firmly consolidated this pathway as a crucial player of
tumourigenesis. The evidence of PTCH mutations in sporadic BCCs, in many cases
with both alleles inactivated by either mutation or loss of heterozygosity supports
that PTCH acts as a putative tumour suppressor gene (Wicking et al., 1997; Gillies et
al., 1997; Gailani et al., 1996). Ptc+/~ mice also displayed a phenotype partly similar
to that ofNBCC patients(Wetmore et al., 2000).
1.5.4.2. SMO and cancer
Mutations in SMO have also been detected in 10-20% of BCCs and primitive
neuroectodermal tumours. In these cases, the mutations appear to activate SMO, and
so activate the HH pathway (Lam et al., 1999; Reifenberger et al., 1998).
1.5.4.3. Glis and cancer
Dysregulation of GLI1 has been implicated in HH pathway diseases. Since the
original isolation of GLI1 from a glioma line (Kinzler et al., 1987), the evidence of
GLI1 involvement in brain tumours has increased more recently. Glil misregulation
was subsequently shown to lead to the development of BCC-like tumours in frog
embryos and mice (Dahmane et al., 1997; Oro et al., 1997), Because the Hh-Gli
pathway is active in precursor populations in a variety of tissues and organs,
deregulation of Glil function is likely to be involved in tumour development in
tissues that utilise the Hh pathway for their development or maintenance. In contrast
to the gain-of-function phenotype of GLI1, there are no human diseases associated
with loss of GLI1 function to date, and in mice Glil appears to be redundant. GLll
has been classified as an oncogene on the basis of its ability to transform cells in
cooperation with adenovirus ElA (Ruppert et al., 1991).
So far, although no defects in GLI2 have been found associated with human diseases,
studies in mice suggest that involvement in basal cell carcinomas, skeletal defects,
and other disorders are likely (Sasaki et al., 1999; Grachtchouk et al., 2000; Park et
al, 2000).
GLI3 frameshift and nonsense mutations have been linked to Pallister-Hall syndrome
(PHS), an autosomal dominant disease involving hypothalamic hamartoma (a kind of
benign midline tumours of the ventral forebrain), central or postaxial Polydactyly,
syndactyly, imperforate anus, anteverted nares and other facial abnormalities, and
associated HPE and malformations of the axial skeleton (Jones 1997; Kang et al..
1997). The mutation in PHS maps to the C-terminus of the GLI3 gene downstream of
the zinc-finger coding region, and would be predicted to give rise to a C-terminally
truncated protein with constitutive repressor activity. This hypothesis is supported by
the fact that in GCPS (Greig cephalopolysyndactyly syndrome) patients do not
develop hypothalamic hamartomas. Mutations in human GLI3 have been implicated
in several types of birth defects. Translocations, deletions, and point mutations
throughout the GLI3 gene cause GCPS, which is characterized by syndactyly,
predominantly preaxial Polydactyly, broad thumbs and first toes, and facial
anomalies such as hypertelorism and frontal bossing (Vortkamp et al., 1991; Jones,
1997; Wild et al., 1997; Kalff-Suske et al., 1999).
2. Colon cancer
2.1. General introduction
After lung and breast cancer, colorectal cancer is the most common cause of death
from malignant disease in the Western world. But unlike for the commonest cause of
lung cancer, the basis of the initiation of this disease is currently not understood.
Fortunately the morphological observation that most colorectal cancers develop from
normal epithelium through sequentially worsening degrees of adenomatous dysplasia
provide a good model for us to study the genetic alterations that underlie the visible
progression (see figure 4).
Colon cancer is usually observed in one of two specific patterns: sporadic, inherited
(or familial). Sporadic disease, with no familial or inherited predisposition, accounts
for approximately 70% of colorectal cancer in the population. Sporadic colon cancer
is common in persons older than 50 years of age, probably as a result of dietary and
environmental factors as well as normal aging. While the majority of cases of
colorectal cancer are sporadic, significant minorities occur as a result of an inherited
genetic mutation. Familial adenomatous polyposis (FAP), the polyposis syndromes
and hereditary non-polyposis colorectal cancer (HNPCC) account for about 5% of all
colorectal cancers (CRCs).
In most colorectal cancers the causative mutations in tumour suppressor genes and
oncogenes occur at different times during tumourigenesis, specifically, adenomatous
polyposis coli (APC) gene mutations, global hypomethylation, K-ras mutations,
deleted in colon cancer (DCC) gene mutations, and finally mutations in the p53 gene.
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Figure 4. Molecular basis of colon adenoma-carcinoma progression
APC mutations initiate the neoplastic process, and tumour progression results from
mutations in the other genes indicated. Patients with FAP inherit APC mutations and
develop numerous dysplastic aberrant crypt foci (ACF), some of which progress as
they acquire the other mutations indicated in the figure. The tumours from patients
with HNPCC go through a similar, though not identical, series of mutations; MMR
deficiency speeds up this process. K-RAS is an oncogene that requires only one
genetic event for its activation. The other specific genes indicated are tumour
suppressor genes that require two genetic events (one in each allele) for their
inactivation. Chromosome 18q21 may contain several different tumour suppressor
genes involved in colorectal neoplasia, with DCC and other genes proposed as
candidates. A variety of other genetic alterations have each been described in a small
fraction of advanced colorectal cancers. These may be responsible for the
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Figure 4. Molecular basis of colon adenoma-carcinoma
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Figure 5. Mechanism of tumour suppressor gene inactivation
In the early 1970s, Alfred Knudson suggested that two mutations or 'hits' were
sufficient for the development of a retinoblastoma and that the inheritance of one of
these mutations could account for the earlier onset and frequent bilateral occurrence
of the hereditary form of this tumour. Subsequent molecular studies supported
Knudson's hypothesis by demonstrating mutations of both alleles of a tumour
suppressor gene-'RBR in both hereditary and sporadic retinoblastomas. In hereditary
retinoblastoma, individuals begin life with a constitutional mutation that inactivates
one allele of the RBI gene. The 'second hit' occurs somatically and usually involves
loss of all or part of the chromosome containing the normal RBI allele. Because of
the nature of this second mutation, other genes and genetic markers in the region of
the normal RBI allele are often lost within the tumour cells as well. If some of these
genetic markers happen to be heterozygous in the individual, loss of one allele on the
same chromosome as the normal RBI allele produces loss of heterozygosity (LOH),
a cell-specific phenotype that is relatively easy to find in tumour tissue. Genes like
RBI that permit tumour development when both alleles are inactivated or lost are
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Figure 5. Mechanism of tumour suppressor gene inactivation
(Knudsen's two hit hypothesis for RB)
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2.2 .p53
There is no doubt about the role of p53 mutations in the progression of colorectal
tumours. Genetic alternation in the p53 gene occur in around 80% of colorectal
cancers, and p53 mutations are rare in adenomas, suggesting that p53 mutations
occur more frequently in high-grade dysplastic polyps and are thought to mark the
malignant transition from adenoma to carcinoma (Baker et al., 1990).
2.3. APC and theWnt signalling pathway
The genetic basis for FAP mainly lies in germline (inherited) mutation of the
adenomatous polyposis coli (APC) gene. About one-quarter of all cases are caused by
mutations that maintain the incidence of FAP (Bisgaard, 1994). The first clue to the
localisation of of the APC gene came from identification of a patient with colorectal
polyposis and mental retardation who had a deletion of the chromosomal fragment
5q21( Herrera,1986). Linkage analysis of families with FAP led to the mapping of
the APC gene to 5q21 in 1987(Bodmer et al., 1987). The APC gene was then cloned,
identified and characterized in 1991(Groden et al., 1991; Kinzler et al., 1991). Exon
15 comprises more than 75% of the coding sequence of APC and is the most
common target for both germline and somatic mutations (Beroud et al., 1996).
Germline mutations in the APC gene have been reported in most FAP patients
(Cottrell et al., 1992). The majority (95%) of APC mutations are nonsense or
frameshift mutations that result in a truncated protein product with abnormal
function. As expected from Knudson's two-hit hypothesis (see figure 5), colon
tumours from FAP patients nearly all harbour either additional somatic APC
mutations or loss of heterozygosity at the APC locus in addition to the original
germline mutation. The type of germline APC mutation in FAP appears to be
correlated with the nature of the second somatic hit to APC. If the germline mutation
occurs between codons 1194 and 1392, then there is strong preference for allelic loss
ofAPC as the second hit in the development of a colorectal adenoma. If the germline
mutation lies outside this region, the second hit in tumourigenesis is most likely to
produce a truncating mutation in the somatic mutation cluster region (MCR) between
codons 1286 and 1513 (Lamlum etal., 1999).
In addition to the role of the APC gene in the aetiology of familial adenomatous
polyposis coli (FAP), mutations in this gene cause sporadic colorectal cancer. APC
mutations, which generally bring about a truncated APC protein (Miyoshi et al.,
1992), or take the form of allele loss (Solomon et al., 1987), are found in about 75%
of sporadic colorectal cancers (Miyaki et al., 1994) and are observed in the earliest
adenomas (Powell et al., 1992). Accumulating evidence shows that the APC may
function as a gatekeeper tumour suppressor in a wide variety of cellular processes
including cytoskeletal organization, migration, adhesion, proliferation, even perhaps
aspects of chromosome stability and the control of cellular proliferation, possibly by
affecting the rate of cell division or apoptosis (Baeg et al., 1995; Su et al., 1993;
Rubinfeld et al., 1993; Browne et al., 1994; Burchill et al., 1994; Munemitsu et al.,
1994).
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Figure 6. The canonical Wnt pathway
Activators of the pathway are white; negative regulators are gray. Left, in the
absence of Wnt stimulation, the Axin complex actively earmarks [i-
catenin/Armadillo (white circles) for degradation by the proteasome. The levels of
cytoplasmic P-catenin/Armadillo are low, and TCF is repressed. Right, after Wnt
stimulation of the Frizzled receptor (arbitrarily drawn to be in the apical membrane),
Dsh is recruited to the membrane where it binds to Axin to inhibit the Axin complex.
P-catenin/Armadillo accumulates and, after translocation into the nucleus, binds to
TCF to coactivate Wnt target genes. Inhibition of the Axin complex by GBP/Frat
appears to be an alternative to Wnt-mediated inhibition. CBP switches from being a
negative regulator to being a coactivator, apparently depending on the stimulation
status of the cell. Note also the apicolateral adherens junctions to which the Axin
complex appears to be anchored. These junctions are formed by the transmembrane
protein E-cadherin (black bars) which is linked to the actin cytoskeleton (thin lines)
by p-catenin/Armadillo and a-catenin (black dots).
Figure 6. The canonical Wnt pathway
(Cell, Vol. 103, 311 320)
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APC plays a major role in the Wnt signalling pathway where, in the absence ofWnt,
its main partners are axin and glycogen synthase kinase 3 P (GSK3P)(Behrens et al.,
1998). In these conditions, the complex actively targets P-catenin for degradation by
the proteasome. In the absence of this regulation, p-catenin escapes degradation and
translocates to the nucleus where it complexes with one of the TCF/LEF
transcription factors and initiates transcription of a wide variety of genes (Polakis,
1999). Mutations of APC inhibit its ability to signal degradation of P-catenin
leading to constitutive activation of downstream genes. In many of those relatively
few colon cases where APC is not mutated, there is a mutation of (P-catenin (Iwao et
al., 1998; Sparks et al., 1998; Mirabelli-Primdahl et al., 1999; Miyaki et al., 1999) or
one of the other members of the pathway (e.g. axin)(Liu et al., 2000 and Webster et
al., 2000).
2.4. K-ras
Although mutations in the APC gene are initiating events in colorectal
tumourigenesis, these mutations are not enough for adenomas to progress
malignancy. Several other genes are involved in the progression of early adenomas to
early carcinomas. More than 50% of colorectal cancers display specific mutations in
the K-ras gene, with an increasing frequency in larger and more advanced lesions
(Fearon and Vogelstein, 1990). The consequence of K-ras mutations during tumour
development may be a growth advantage of those cells with both APC and K-ras
mutations over cells with APC mutations alone.
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2.5. DCC and chromosome 18q
During the past 10 years, other mutations that occur in colorectal cancer have been
identified. The DCC gene was identified as a result of the frequent allele loss close to
its location on 18q21.3 in colorectal cancers (Vogelstein et al., 1988). DCC is a
neural cell adhesion molecule homologue and DCC mutations may therefore have a
role in colorectal tumour progression, invasion and metastasis. Although genetic
mutations occur relatively infrequently (Cho et al., 1994), a high incidence of
reduced expression has been reported (Shibata et al., 1996; Saito et al., 1999). This
may be due to the allelic imbalance (seen as LOH), and the role of DCC in colorectal
carcinogenesis remains equivocal. Apart from DCC, there is also evidence showing
that SMAD4 is also a target of allele loss on chromosome 18q in some cancers.
Smad4 acts as a cofactor that binds transforming growth factor-p (TGF-P) receptor-
activated Smad2 and Smad3 generating transcriptional complexes (Lagna, 1996).
Inactivating mutations in Smad4/DPC4 can cause the post-receptor defects of TGF-P
and so promote cell proliferation. Following the initial identification of Smad4
mutations in half of all pancreatic carcinomas (Flahn et al., 1996), Smad4 mutations
were reported in colon cancer (Takagi et al., 1996; Thiagalingam et al., 1996; Howe
et al., 1998) and other gastrointestinal cancers (Powell et al., 1997). In colon cancer,
the incidence of Smad4 mutations appears to increase with tumour progression
(Howe et al., 1998). Although it is rare as an initiating event and relatively infrequent
(approximately 10% of cases) in colon adenomas and nonmetastatic carcinomas
(Riggins et al., 1997), Smad4 mutations have been reported in more than 30% of
invasive metastatic carcinomas and in colon cancer metastases (Miyaki M et al.,
1999).
2.6. LKB1 and chromosome 19
Chromosome 19 abnormality is also a feature in some cancers. The evidence that
chromosome 19 might harbour tumour suppressor genes was found in lung cancer
(Virmani et al., 1998; Sanchez-Cespedes et al., 2001) and prostate cancer (Gao et al.,
1999). In these studies, the deletions of chromosome 19 were observed in cancer cell
lines and primary tumours.
LKB1, also STK11 or LKB1/STK11 is located on chromosome 19p 13.3 (Hemminki et
al., 1997) and encodes a serine-threonine kinase, a human homologue of Xenopus
early embryonic kinase 1. (Su et al., 1996). LKB1 is suggested to act as a tumour
suppressor gene in PJS (Peutz-Jeghers syndrome) as hamartoma formation in PJS
patients with inactivating LKB1 germline mutations is associated with somatic loss of
the wild-type LKB1 allele. (Hemminki et al., 1997, Gruber et al., 1998; Trojan et al.,
1999)
The development of cancer in patients with PJS does not only arise in association
with hamartomas (Giardiello et al., 1987) but dysplasia with consecutive neoplastic
transformation within hamartomatous polyps accounts for at least some malignancies
in this syndrome (Spigelman et al., 1989; Boardman et al., 1998). In contrast with
the tumourigenesis of sporadic colorectal cancer, which is frequently involving APC,
K-ras, DCC andp53,( Kinzler and Vogelstein, 1996; Lynch, 1998; Vogelstein et al.,
1988) the molecular mechanisms of cancer in PJS patients remain unclear. Since
patients with PJS are prone to develop colorectal cancer, LKB1 may also be a
vulnerable target during the pathogenesis of sporadic colorectal cancer. Although
some reports showed a low frequency of somatic mutations of the LKB1 gene in
colorectal tumour, (Aviziente, 1998; Wang, 1998; Resta, 1998) conflicting data were
reported by Dong and colleagues (Dong, 1998). This group identified somatic LKB1
mutations in one third of left sided colorectal cancers and in two colonic adenomas.
Also, silencing of LKB1 associated with promoter hypermethylation was found in a
few cancer cell lines and primary tumours (Esteller, 2000).
2.7. DNA mismatch repair genes
Mutations in three MMR genes primarily cause the dominantly inherited syndrome
hereditary non-polyposis colorectal cancer (HNPCC): MSH2 on chromosome 2p,
MLH1 on chromosome 3p, and MSH6 on chromosome 2pl6(Leach et al., 1993;
Fishel et al., 1993; Aaltonen et al., 1993; Kolodner et al., 1999). Colorectal cancers
from patients with mutations in these MMR genes consistently show microsatellite
instability (MSI), a form of replication error (RER). It is generally accepted that
mutations in the MMR genes in HNPCC families act to not only increase the
mutation rate of the whole genome, but promote tumourigenesis when a gatekeeper
gene (e.g. APC) is affected. MSI also occur in ~15% sporadic Colorectal cancers
(CRCs), but is mainly due to hypermethylaion of MLH1 (see next section), and
mutation of MSH2 to a lesser extent (Liu et al., 1995). Like p53 mutations, MMR
abnormalities often occur in late colonic adenomas, and are therefore involved in the
progression of tumours rather than initiation (Tomlinson et al., 1996).
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2.8. Other genes in colon carcinogenesis
Other genes such as PTEN (Zhou et al., 2002), FHIT (Mady and Melhem, 2002), pi6
(Herman et al., 1995) and NM23 (Hsu et al., 1995) have been found to be involved in
colorectal tumourigenesis in a small proportion of cancer. PTEN and FHIT may play
a role as serine/threonine kinase and protein kinase B (PKB) inhibitors. pl6 is an
important member of the cell cycle control system. NM23 is associated with cell
adhesion and metastasis of several cancers.
2.9. Epigenetic events in colon cancer
In addition to common deletions and inactivating mutations, epigenetic events have
recently been recognised as an alternative mechanism of gene silencing. The
hypermethylation of CpG islands in the promoter region, an important epigenetic
mark, has been found important for colon cancer by reports of homozygous promoter
hypermethylation of the hMLHl gene in about 80% of sporadic RER+ tumours
(Cunningham et al., 1998). In addition, promoter hypermethylation has been shown
associated with the silencing ofpl6 in some colorectal cancer cell lines and patients.
One group found that Drg-1 was silenced by promoter hypermethylation (Guan et
al., 2000). It is a differentiation-related and putative metastatic suppressor gene. It
may induce colon cancer cell differentiation and partially reverse the metastatic
phenotype. CDX1, a homeobox protein that inhibits proliferation of intestinal
epithelial cells and regulates intestine-specific genes involved in differentiation, was
reported to be down regulated by aberrant methylation of the CpG island in the
CDX1 promoter colorectal cancer cell lines (Suh et al., 2002). Recently, one study
showed SLC5A8, a sodium transporter, was silenced by methylation in human colon
aberrant crypt foci and cancers and suggested that it may be a tumour suppressor
gene (Li et al., 2003).
3. Lung cancer
3.1. General introduction
Lung cancer has become the leading cause of cancer death in many industrialised
countries. A better understanding of the molecular pathogenesis of this fatal disease
is thus urgently needed in order to provide effective preventive (other than
abstinence) or therapeutic routes for clinical management. It is widely accepted that
carcinogens in the cigarette smoke are major triggers of lung cancer by the formation
of DNA adducts that induce multiple genetic alterations. Well functioning cell cycle
regulation and checkpoints are crucial for maintaining genomic integrity by allowing
time for repair of damage, and their abnormality are thought to contribute to genomic
instability, thus playing an important role even in the early steps of cancer
development. Many of the tumour suppressor genes and oncogenes altered in lung
cancer are believed to play a role in the regulation of cell cycle progression in either
a direct or an indirect manner, and a large proportion of the lung cancer-related genes
are a component of the checkpoint mechanisms (see table 1).
3.2. p53
Loss of Heterozygosity at 17p 13, which contains p53, is very frequent in lung
cancer, associated with mutation of the other p53 allele. Such inactivation of p53
38
occurs in -90% of SCLC (Small cell lung cancer) and 40-70% of NSCLC (Non-
small cell lung cancer)(Harris, 1996).
3.3. RB
The RB gene is located on chromosome 13ql4, and its protein product is a nuclear
phosphoprotein initially identified as a tumour suppressor gene in childhood
retinoblastomas. The phosphorylation status of the RB protein and its interaction
with transcription factor E2F is one of the most important determinants in the
regulation of G0/G1 transition. Abnormalities of the RB gene in lung cancer include
deletions, nonsense mutations and pathogenic splicing variations. More than 90% of
the SCLCs, and 15-30% of the NSCLCs have abnormal or no RB expression
(Reissmann et al., 1993, Cagle et al., 1997 and Dosaka-Akita et al., 1997). In
addition germline carriers of a RB mutation are 15 times more likely to die from lung
cancer than unaffected individuals (Sanders et al., 1989).
3.4.pl6
pl6/INK4 is an inhibitor of RB phosphorylation and thus it is also a tumour
suppressor gene. The pl6/INK4 gene is most commonly altered in NSCLCs by
aberrant promoter methylation (25%)(Zochbauer-Muller et al., 2001; Merlo et al.,
1995) and homozygous deletions or point mutations (10%-40%)(Rusin et al., 1996;
Marchetti et al., 1997; Shapiro et al., 1995; Okamoto et al., 1994). In lung cancer,
apart from mutational inactivation, promoter region methylation has been found to be
a major alternative mechanism silencing the expression ofpi 6.
39
3.5.pi9
pl9/ARF is a p 16 splice variant leading to an altered reading frame from pl6/INK4.
pl9/ARF was shown to play an important role in tumour suppression with binding to
the MDM2-p53 complex and thus preventing p53 degradation. pl9/ARF was found
more frequently lost in lung tumours with neuroendocrine features(Gazzeri et al.,
1998). Thus the pl6/INK4 pl9/ARF locus products interact with both the Rb and
p53 pathways.
3.6. Other candidate tumour suppressor genes for lung cancer
The most significant chromosome event is the abnormality of chromosome 3p in
SCLC and NSCLC samples. This region harbours many candidate genes in 4
localised regions (3p25-p26, 3p21-p22, 3pl4, and 3p 12) (Hibi et al., 1992; Latif et
al., 1992), which are undergoing active investigation. These genes include retinoic
acid receptor genes, phosphatase genes, members of the ubiquitin activation family,
DUTT1, BAP1, RASSF1A and many others. The most prominent candidate
chromosome 3p gene is the FHIT gene at 3pl4.2 which undergoes genomic
alterations with absent protein expression in a large subset of human lung tumours
(Zochbauer-Muller et al., 2001). The function of its protein product and its role in
lung tumourigenesis, however, is still unknown.
3.7. Ras
The dominant oncogene RAS plays a key role in signal transduction and cell
proliferation. RAS mutations are rare or non-existent in SCLC, but are present in 15-
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20% of NSCLC. Up to 30% of the adenocarcinomas carry RAS mutations usually
affecting codon 12 for KRAS (85% of cases,), and uncommonly codon 13 of HRAS
and codon 61 ofNRAS (Richardson and Johnson, 1993).
3.8. MYC
The MYC proto-oncogenes {MYC, MYCN, and MYCL) encode nuclear
phosphoproteins that have a role in transcriptional regulation by heterodimerizing
with proteins such as MAX, MAD or MX11. The MYC-MAX complex represses
transcriptional activation. MAX can bind MAD and MX11, thereby MYC is released
from the complex and functions as a transcriptional activator. MYC can cooperate
with a mutant RAS gene to transform primary rat embryo fibroblasts to malignancy.
The activation of the MYC genes by amplification or loss of transcriptional control
resulting in protein overexpression is a major molecular mechanism in the
pathogenesis of human lung cancers. MYC gene activation has been observed in both
NSCLC and SCLC whereas NMYC and LMYC abnormalities mainly occur in SCLC.
MYC amplification occurs in 15-30% of SCLC and 5-10% of NSCLC (Richardson
and Johnson, 1993).
3.9. Epigenetic events in lung cancer
Gene expression can be turned off by aberrant promoter methylation in cancer as
mentioned before. Alteration in 5'-CpG island methylation has been reported for
several genes in lung cancer (Esteller et al., 1999). One recent study shows that 8
genes are aberrantly methylated in NSCLC. Specifically, RARB in 40%,
metalloproteinase-3 inhibitor (TIMP-3) in 26%, p!6INK4a in 25%, 06-
methylguanine-DNA-methyltransferase (MGMT) in 21%, death-associated protein
kinase (DAPK) in 19%, E-cadherin (ECAD) in 18%, pl4ARF in 8% and glutathione-
S-transferase PI in 7% samples tested were hypermethylated (Zochbauer-Miiller et
al., 2001).
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4. Summary and aims
It is well known that cancer progression is a multi-step process and that multiple
genetic and epigenetic events will occur in tumours. Given that there are about 3 x
109 nucleotides encoding more than 30000 to 40000 genes in the human genome,
identifying these genetic and epigenetic abnormalities is a difficult task. This is
further complicated by the fact that since tumour cells are genetically and
epigenetically unstable, a range of abnormalities may additionally occur in genes that
are not involved in the initiation and/or development of the tumour.
Despite this complexity, many genes that are involved in tumourigenicity have been
identified, some of which are common to many tumour types and some of which are
more restricted in their tissue distribution. The techniques used to discover these
genes have included loss of heterozygosity analysis, positional cloning, cloning of
chromosomal breakpoints, candidate gene analysis and combinations of these. In
both types of cancer many genes have been identified, some common to both (e.g.
p53) and some specific to one (e.g. APC in colon). Damage to these genes in lung
cancer seems to have a relatively random pattern, perhaps due to the massive
chemical assault caused by smoking, whereas a particular pattern of genetic and
epigenetic events is generally thought to occur in sporadic colon cancers as cells
progress from normal to malignant stages.
However, there are still many gaps to be filled. For example, there are chromosomal
regions that are known to suffer loss of heterozygosity that harbour tumour
suppressor genes, but for which there is a relatively limited incidence of abnormality
in the cases studied. This disparity of LOH and gene abnormality suggests a lack of
complete analysis of the known tumour suppressor gene by techniques to screen for
all forms of potential inactivation (e.g. mutations are known already but epigenetic
screening has not been done to look for silencing of the gene), or it suggests the
association of another gene from the region. So, for example in the case of colon
cancer, LOH occurs at chromosome 18q21 in about 65% of cases, but mutations of
the known tumour suppressor genes of the region (DCC, SMAD4) occur at lower
frequencies (5% and 10~30%). This implies either another neighbouring gene of
greater importance or some combination of known and unknown tumour suppressor
genes from the area is necessary for tumourigenesis. The same is true for lung cancer
in 18q21, and for both cancers in chromosome 19p 13, where this thesis will address
the role of candidate genes as outlined below.
It is also possible that other pathways are disrupted or disregulated that are not part
of the current paradigm of tumourigenesis, especially the much favoured genetic
steps in the adenoma-carcinoma progression of colon cancer. Reasons for the need to
keep an open mind on this include several observations. For example, the paradigm
involves mutations in all of the three main genes studied (APC, K-ras and p53), but
in a study of all of these genes in a set of colon cancers by Smith et al. (Smith et al.,
2002) they found only 6% had all three mutations and a significant percentage had a
mutation in only any one of them. They concluded that the mutations lay on alternate
pathways of colorectal development. Similarly, although many of the genes found to
be abnormal in colon cancers derived from ulcerative colitis are the same as those in
sporadic cancers, the frequencies of defects are significantly different so as to
indicate an alternative molecular pathway for aetiology (Wong and Harrison, 2001;
Benhattar and Saraga, 1995).
The aim of this study was to take the candidate gene approach to test two examples
of genes or intracellular pathways that could control or suffer epigenetic changes in
colon and lung cancer:
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1) to continue the investigation of members of the MBD family whose proteins
are important in recognition of methylation patterns and epigenetic regulation
of other genes.
MBD2: This gene lies within chromosome region 18q21, a major zone of LOH in
colon and lung cancers, near to the DCC and SMAD4 tumour suppressor genes. A
survey for mutations in MBD2 was published by our group (Bader et al., 2003) in
which it was reported that the gene suffered few changes. However, mRNA levels of
MBD2 are reported to be reduced in colon and lung tumours (Kanai et al., 1999,
Miiller-Tidow et al., 2001) suggesting inactivation by gene silencing is more
important for this gene. The aim of this study was therefore to screen our own set of
cell lines for expression and the presence of methylated sequences in the putative
promoter region ofMBD2.
MBD3: This gene is located within chromosome region 19p 13, a zone of LOH, and
within 500kbp of the LKB1/STK11 tumour suppressor gene. The latter gene is
involved in cancers from patients with Peutz-Jeghers syndrome but is relatively
rarely affected in sporadic colon cancers or lung cancers. MBD3 is thus a suitable
alternative candidate and this study aimed to screen for mutations, abnormalities of
expression or methylation of the promoter of this gene.
2) to investigate the Hedgehog pathway whose activity is involved in normal
tissue development.
As stated above, the Hedgehog pathway is both important in colon and lung
development and has been implicated in tumourigenesis of certain other tissues.
Preliminary data from our laboratory has shown that proteins of the hedgehog
pathway are still expressed in normal adult (as opposed to foetal) colon and also in
hyperplastic, adenomatous and carcinomatous colon tissues. It was therefore of
interest to assay genes of the pathway for mutations and abnormalities of methylation
or expression at the RNA level, to see if Hh signalling is an alternative pathway of
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l.Cell culture and primary tumour samples
l.l.Cell culture
Aseptic techniques were strictly applied and cells were inspected frequently to ensure
they were in good condition without microbiological contamination. All cell lines
were cultured in RPMI-1640 medium supplemented with 5% FBS and incubated at
37°C with 5% C02.
Cell feeding
Prewarmed media were used and cells were taken out of the incubator for as little
time as possible, 10-15 ml for T-25's, 25-35 ml for T-75's and 50-60 ml for T-150's.
For adherent cells, about every 2-3 days, old media was aspirated from culture flasks
and replaced with fresh media.
Subculturing adherent cells
When adherent cells became 80% confluent, they were subcultured using
trypsin/EDTA. Medium was removed from culture dish and cells were washed in
PBS. The wash solution was removed. An appropriate amount of trypsin-EDTA
solution was added to cover the bottom of the culture vessel. The culture was placed
in the 37°C incubator for 2 minutes. Cells were monitored under microscope. Cells
were beginning to detach when they appear rounded. As soon as cells were in
suspension, culture medium containing serum was immediately added. Cells were
washed once with serum containing medium and diluted as appropriate (generally 4-
20 fold).
Harvesting
Cells were harvested (for RNA) when they were still growing in log phase, before
they had reached a population density that suppresses growth. Medium was removed
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from culture flask and cells were washed in PBS. An appropriate amount of trypsin-
EDTA solution was added to cover the cell layer. The culture was incubated 37°C
incubator for an appropriate time. Then cells were collected as normal.
1.2. Primary tumour samples
Primary colon tumour samples were part of an unselected, anonymised collection
from patients at the Royal Infirmary Edinburgh. DNAs had been extracted from
small portions of frozen samples, prior to the start of this study.
2.DNA manipulation and techniques
2.1.DNA preparation from culture cells
Suspension cultures were pelleted out of its serum-containing medium. Adherent
cells were trypsinized and collected from the flask. Cells suspension was centrifuged
5 min at 500 x g, and supernatant was discarded. Cells were resuspended with 1 to
10 ml ice-cold PBS. Cells suspension was centrifuged 5 min at 500 x g and
supernatant was discarded. This resuspension and centrifugation step were repeated
once. Cells were resuspended in 1 volume digestion buffer (lOOug/ml protease K,
lOmmol Tris-Cl-ph8.0, 15mmolNaCl, lOmmol EDTA-pH8.0, 0.4%SDS). For <3
xlO7 cells, 0.3 ml digestion buffer was used. For larger numbers of cells 1 ml
digestion buffer/108 cells was used. The sample was incubated with shaking at 50°C
for 12 to 18 hr in tightly capped tubes. The sample was thoroughly extracted with an
equal volume of phenol/chloroform/isoamyl alcohol. The sample was centrifuged 10
min at 1700 x g. The aqueous (top) layer was transfered to a new tube and 1/10 vol
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of 3 M sodium acetate and 2 vol (of original amount of top layer) of 100% ethanol
were added. The DNA formed a stringy precipitate. DNA was recovered by
centrifugation at >8000 x g for 15 min, 4°C. The pellet was rinsed with 70% ethanol.
Ethanol was decanted and the pellet was air-dried. DNA was resuspended at ~1
mg/ml in TE buffer until dissolved. The DNA solution was shaked gently at room
temperature or at 65°C for several hours to facilitate solubilization. DNA was stored
indefinitely at 4°C.
2.2.DNA quantification
Spectrophotometric method. For pure solutions of DNA, the simplest method of
quantification was acquired by reading the absorbance at 260 nm where an OD of 1
in a 1 cm path length = 50 ug/ml for double-stranded DNA, 40 ug/ml for single-
stranded DNA and RNA and 20-33 ug/ml for oligonucleotides. An absorbance ratio
of 260 nm and 280 nm gave an estimate of the purity of the solution. Pure DNA and
RNA solutions have OD260/OD280 values of 1.8 and 2.0, respectively.
2.3.Extraction of DNA from low-melting temperature agarose
Gel slice containing DNA was cut out, as smallest size as possible. The volume was
estimated and doubled with TE (10 mM Tris-HCl, pH 8.0/1 mM EDTA). And then
the solution was melt at 65 °C, 5-10 min. One volume Tris-buffered phenol was
added and mixed by inversion at room temperature. The sample was spun 15 min at
10-12k rpm, 4°C and aqueous phase was transfered to new tube. Phenol extraction
was repeated once. The sample was transfered to new tube. One ul carrier
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(glycogen), 1/10 vol of 3 M sodium acetate and 2.5 volumes cold ethanol were added
and mixed, left at -70 C 5-10 min, and spun as above, 10 min. Pllet was washed with
1 ml 70% ethanol, dried under vacuum, and resuspended in 10-20 ul water or TE.
2.4. Agarose gel electrophoresis ofDNA
One gram agarose was dissolved in 100 ml of lx TAE or TBE buffer (gives a 1%
gel). 10 pi ethidium bromide solution per 100ml of buffer was added. The gel was
cast with the comb in place. 6x gel loading buffer was added to sample and the
samples were loaded into wells. The gel was run in lx TAE or TBE (30-60 min. at
100-150V). The photo was taken on a long wave UV transilluminator.
2.5. Polymerase chain reaction (PCR)
Following reagents were added to a microfuge tube: 10 ul reaction buffer, 5 ul 20 uM
forward primer, 5 ul 20 uM reverse primer, 1 ul template DNA, 16 ul 1.25 uM dNTP,
3 ul 50 mM MgC12 or MgS04 (volume variable) and water (to make up to 100 ul).
The tube was placed in a thermocycler. Sample was heated to 95 °C, then 0.5 -1 ul of
enzyme (Taq, etc.) was added. A few drops of mineral oil were added to cover the
reaction solution. The PCR cycles were started according the following schemes: a)
denaturing - 94 ° C, 30-90 sec. b) annealing - 55 °C (or Tm -5°), 0.5-2 min. c)
extending - 72 °C, 1 min. (time depends on length of PCR product and enzyme
used). Cycles were repeated 30 times. A final extension step of 5 min was added to
fill in any uncompleted polymerisation. Then the reaction was cooled down to 4- 25
°C.
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When high CG content DNA needed to be amplified, Pfx polymerase with
appropriate amount of enhancer solution was used to provide high fidelity PCR
product.
2.6. Restriction digest of DNA
For a typical digestion of 10 pg ofDNA, water was added to a volume of 17 pi. Two
pi of the appropriate lOx reaction buffer and 1 pi of enzyme were added. The sample
was incubated at 37 °C for 2-16 hours. DNA was run on gel. For double digestion
with 2 different restriction enzymes, both enzymes were added at the same time if
they use the same buffer. If not, digested with one enzyme, precipitated the DNA.
Then the DNA was resuspended and digested with the second enzyme in its
appropriate buffer.
2.7.DNA sequencing
The following protocol used USB Sequenase DNA sequencing kit
Pre-treatment of PCR product
Ten ul PCR product, 2ul Exo, 2ul SAP were added in 0.5ml tube. The sample was
heated at 37°C 15min, 80°C 15min and then put on ice.
Preparation of reaction mix
The following reagents were added: 2ul reaction buffer (5x), DNA (7ul), lul primer
(20uM), 8ul double distilled water and 2ul sequenase
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Preparation of termination mix
Four tubes were prepared for each labelling reaction of ddGTP,ddATP, ddTTP and
ddCTP. The following reagents were added to each tube: 2ul master mix and 0.5ul a-
33p(ddNTP).
Cycle sequencing
4.5ul reaction mix was added to each termination mix. Normal PCR cycles were
applied, PCR condition varied with different template. Stop solution (4ul) was added,
mixed and kept on ice.
Preparation of sequencing gel
Plates were cleaned with ethanol and one side of the shorter plate was siliconised.
Spacers were put between plates. Plates' sides were clamped with clips to form
mould. The combs were checked to make sure that they fit between plates. Plates
were laid on horizontal surface. Gel mixture was prepared (6% sequence gel, 555ml)
as following: 240g Urea, 75ml 40% acrylamide solution, 50ml TBE (10x), and
190ml H20. To start polymerisation reaction, following reagents were added: 60ml
6% sequence gel solution, 400ul 10% APS, and TEMED 30ul. Gel mixture was
mixed and cast quickly. Combs were put in place with the straight side down. Gel
was left to polymerise. When gel had set, tape and comb were removed. The wells
were rinsed. Plates were placed in electrophoresis apparatus. Combs were placed
with the serrated edge down into the well, with the teeth just slightly penetrating the
gel. Top and bottom tanks were filled with lx TBE. Wells were rinsed to remove any
bubbles and particles. A pre-run (80W, 30 min) was performed before samples were
loaded to preheat the gel.
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Sample loading
Samples were heated to 95 °C for >3 min, then put on ice immediately. Wells were
rinsed to remove any bubbles. 4ul of sample was loaded in the sequence GATC or
ACGT.
Electrophoresis of DNA
Gel was run at constant power (80W) for ~ 2 - 4 hours. If second loading of sample
was needed, the second sample was loaded after the xylene cyanol light blue dye had
reached the bottom.
Gel drying
After the electrophoresis had finished, spacers and plates were removed from
apparatus. The plates were taken apart carefully to make sure that the gel only sticks
to the longer plate. A large piece of Whatman paper was placed on gel and gel was
transferred onto the paper from plate. Cling film was placed on gel. Gel was dried in
gel dryer (80 °C under vacuum).
2.8. PCR cloning
2.8.1. Set up ligation (pGEM-T Easy Vector System)
The pGEM®-T Easy Vector tube was briefly centrifuged to collect contents at the
bottom of the tube. The 2x Rapid Ligation Buffer was vigorously vortexed before
each use. Ligation reaction was set up as described below. 2xRapid Ligation Buffer
5pi, PCR product 4pl, pGEM®-T Easy Vector 0.5pl and T4 DNA Ligase 0.5pl were
added to a tube. The reaction was incubated in 16°C for overnight.
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2.8.2.Transformation (One Shot. TOPIO Competent Cells)
The vial containing the ligation reaction was centrifuged briefly and placed on ice.
One 50ul vial ofOne Shot® cells was thawed on ice for each ligation/transformation.
1 to 5ul of each ligation reaction was pipetted directly into the vial of competent cells
and mixed by tapping gently. The vial was incubated on ice for 30 minutes. Then the
vial was incubated for exactly 30 seconds in the 42°C water bath. The vial was
removed from the 42°C bath and placed on ice. 250ul of pre-warmed S.O.C medium
was added to the vial. The vial was placed in a microcentrifuge rack on its side and
secured with tape to avoid loss of the vial. The vial was shaked at 37°C for exactly 1
hour at 225 rpm in a shaking incubator. 20ul to 200ul from transformation vial was
spreaded on separate, labeled LB agar plates with 50ug/ml ampicillin and X-gal. The
remaining transformation mix was stored at +4°C and plated out the next day, if
desired. The plate was inverted and incubated at 37°C overnight. White colonies
were selected with tooth sticks and analyzed by lysates PCR of boiled lysates.
2.9.Plasmid isolation (Qiagen Plasmid Preparation Kits)
All steps were carried out at room temperature.
Things done before starting:
The provided RNase A solution was added to Buffer PI before use. One vial of
RNase A (spin down briefly before use) was used for one bottle of Buffer PI, to give
a final concentration of lOOpg/ml. Buffer P2 was checked for SDS precipitation due
to low storage temperatures. If necessary, the SDS was dissolved by warming to
37°C. Buffer P3 was pre-chilled to 4°C.
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2.9.1. Plasmid mini-preparation
To purify up to 20pg of high-copy plasmid (pGEM-T) DNA froml-5ml overnight
cultures ofE. coli in LB medium. A single colony was picked from a freshly streaked
selective plate and inoculated a culture of 5ml LB medium containing the appropriate
selective antibiotic. The culture was incubated for 16—18h at 37°C with vigorous
shaking (~300rpm). The bacterial cells were harvested by centrifugation at 6000 x g
for 15min at 4°C. Pelleted bacterial cells were resuspended in 250pl Buffer PI
(containing RNase A) and transfered to a microcentrifuge tube. 250pl Buffer P2 was
added and the tube was gently inverted 4-6 times to mix. 350pl Buffer N3 was added
and the tube was inverted immediately but gently 4-6 times. The tube was
centrifuged for lOmin at maximum speed in a tabletop microcentrifuge. A compact
white pellet would form. The supernatant was applied to the QIAprep column by
decanting or pipetting. The column was centrifuged for 30-60s. The flow-through
was discarded. QIAprep spin column was washed by adding 0.75ml Buffer PE and
centrifuging for 30-60s. The flow-through was discarded. The column was
centrifuged for an additional 1 min to remove residual wash buffer. The QIAprep
column was placed in a clean 1.5ml microcentrifuge tube. To elute DNA, 50pl
Buffer EB (lOmM Tris-Cl, pH8.5) or water was added to the center of each QIAprep
column. The column was let stand for lmin, and then centrifuged for lmin.
2.9.2. Plasmic midi/maxi preparation
This procedure was to prepare up to lOOpg /2.5mg of plasmid from 25ml/500ml
overnight cultures of E. coli in LB medium. A single colony was picked from a
freshly streaked selective plate and inoculated a starter culture of 2-5ml LB medium
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containing the appropriate selective antibiotic. The culture was incubated for ~8 h at
37°C with vigorous shaking (-300 rpm). A tube or flask with a volume of at least 4
times the volume of the culture was used. The starter culture was diluted 1/500 to
1/1000 into selective LB medium. For high-copy plasmids (pGEM-T), a culture of
25ml/500ml medium was inoculated and growed at 37°C for 12-16h with vigorous
shaking (~300rpm). A flask or vessel with a volume of at least 4 times the volume of
the culture was used. The culture should reach a cell density of approximately 3-
4xl09 cells per ml, which typically corresponds to a pellet wet weight of
approximately 3g/liter medium. The bacterial cells were harvested by centrifugation
at 6000 xg for 15min at 4°C. The bacterial pellet was resuspended in 4ml/50ml of
Buffer PI. 4ml/50ml of Buffer P2 was added, mixd gently but thoroughly by
inverting 4-6 times, and incubated at room temperature for 5min. 4ml /50ml of
chilled Buffer P3 was added, mixed immediately but gently by inverting 4-6 times,
and incubated on ice for 15min. The tube was centrifuged at 20,000 xg for 30 min at
4°C. Supernatant containing plasmid DNA was removed promptly. The supernatant
was centrifuged again at 20,000xg for 15 min at 4°C. Supernatant containing plasmid
DNA was removed promptly. A QIAGEN-tip 100 /2500column was equilibrated by
applying 4ml QBT, and the column was allowed to empty by gravity flow. The
supernatant was applied to the QIAGEN-tip 100/2500 column and allowed to enter
the resin by gravity flow. The QIAGEN-tip 100/2500 was washed with
2xl0ml/2x 100ml Buffer QC.
Buffer QC was allowed to move through the QIAGEN-tip 100/2500 by gravity flow.
DNA was eluted with 5ml/35ml Buffer QF. DNA was precipitated by adding
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3.5ml/24.4ml (0.7 volumes) room-temperature isopropanol to the eluted DNA. The
DNA was mixed and centrifuged immediately at 15,000xg for 30 min at 4°C. The
supernatant was carefully decanted. DNA pellet was washed with 2ml/7ml of room
temperature 70% ethanol, and centrifuged at .15,000xg for 10 min. The supernatant
was carefully decanted without disturbing the pellet. The pellet was air-dried for 5-
lOmin, and redissolved the DNA in a suitable volume of buffer (e.g., TE buffer,
pH8.0, or lOmM Tris-Cl, pH8.5).
2.10.DNA methylation analysis
2.10.1. Methylation sensitive restriction enzyme analysis
By using the isoschizomer pair (e.g. Hpall/Mspl and Smal/Xmal) which display
differential sensitivity to cytosine methylation, a simple PCR was used to assay the
DNA methylation status of restricted DNAs. The selection of enzymes varied
according to different CpG sequence with different recognised sites, to ensure
enough sites are assayed. The presence of the PCR product from Hpa II or Smal and
other methylation sensitive enzymes digest indicates that the DNA is protected by
methylation from being cut, while no PCR product results if the DNA is not
methylated. No PCR product will be obtained from Mspl and Xmal digested DNA
because they cut irrespective of its methylation status.
Restriction:
lug genomic DNA was used for restriction, 20units enzyme was added in
50ul reaction volume. The digestion was incubated overnight at 37°C (or
appropriate temp.) in water bath.
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Precipitation:
Normal ethanol precipitation was used to precipitate DNA. The DNA pellet was
washed with 70% ethanol once.
PCR detection
The samples cut by methylation non-sensitive restriction enzyme Mspl but not cut by
methylation sensitive restriction enzyme Hpall are methylated.
2.10.2. Bisulfite modification ofDNA
20mM hydroquinone (Sigma; #H 9003) and 4.8M sodium bisulfite (Sigma; #S 8890)
were prepared immediately before use. Above solutions were dissolved by gently
inverting with a minimum amount ofmixing and kept cold and in the dark as much
as possible. 2.5pg DNA was denatured by adding freshly prepared NaOH (3M) to a
final concentration of 0.3M, and then incubated at 42°C for 30min. 500pl 4.8M
sodium bisulfite and 30pl 20mM hydroquinone were added to denatured DNA tube.
The tube was gently mixed and overlaid with mineral oil. The tube was wrapped with
aluminium foil to shield from the light. The tube was incubated at 55°C for 16—18h.
DNA was precipitated by 0.6 volume isopropanol, 0.3M NaOAc and 2.5ul glycogen.
The solution was mixed and centrifuged at max speed for 30mins at room
temperature. The pellet was washed carefully with 70% ethanol and air-dried for
about 1 hour. TE was added to a final volume of lOOpl. The sample was desulfited
with freshly prepared NaOH (as above) and incubated at 37°C for 15min. The DNA
was precipitated with three volumes of ethanol, centrifuged for lOmin
(14,000rev/min) at room temperature, washed twice with 70% ethanol and dried
under a vacuum. Resuspended in lOOpl TE, and stored at -20°C wrapped in foil.
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Treated DNA was used within two weeks as degradation still occurs in the cleaned
and frozen sample.
Care was taken to make sure that the DNA was completely denatured prior to and in
the presence of the bisulfite solution or the modification would not be complete. To
ensure complete denaturation, no more than 5pg of starting material was used, the
DNA was digested with restriction enzymes and the initial alkaline denaturation was
at 42°C for 30min.
2.10.3. Primer design for bisulfite converted DNA sequence
When primers were designed for bisulfite converted DNA sequence, particular
attention was paid to remember that after bisulfite modification, all the unmethylated
C except methylated C had changed to U (recognised by Taq as T). Briefly, sequence
was copied and pasted into a text editor software. All CG was first converted to XG.
Then all C was converted to T. And then all X was converted to C. A restriction map
of this converted sequence (methylated map) was made. All remaining C was
converted to T. A restriction map of this converted sequence (unmethylated map)
was made. Restriction enzyme sites that are unique to the methylated map (not in the
unconverted or unmethylated map) were selected. These were the best to use. If none
was available, restriction sites that are present in the methylated map but absent in
the unmethylated map were selected. Primers were designed for PCR of a region that
containes usable enzymes and that is close to the transcription start. The
methylated/converted sequence was used to design primers, but having C in the sense
primer or G in the anti-sense primer was avoided. If no suitable primers was found,
up to one C was included in each primer, but they are in the 5' end of the primer and
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they were synthesized with a mix of C and T (sense strand) or a mix of G and A
(antisense strand) instead of simply C or G. PCR was amplified with the calculated
annealing temperature and optimised PCR condition.
2.10.4. Experiment procedure for sequencing bisulfite converted
DNA
Bisulfite-PCR products were subcloned into pGEMTand multiple clones (usually 10)
were sequenced to get more methylation detail than other methods. Any C in the
sequence reflects methylation. Nested primers were used to improve PCR
proficiency.
Outline steps:
1) bisulfite treatment described as before
2) nested PCR
3) cloning described as before
4) cycle sequencing described as before
2.11. Single-strand conformation polymorphism analysis (SSCP)
PCR reaction was set up according to standard recipe (see table2). Optimised PCR
conditions was applied to each PCR reaction
MDE Buffer
590ml H2O, 60ml lOxTBE, and 100ml Glycerol were added to make 750ml solution.
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SSCP Gel
To make 50ml gel, 12.5ml MDE gel, 37.5ml MDE buffer, 400pl 10% APS, and 30f.il
TEMED were added. Gel was cast with appropriate sharkstooth comb. Gel would
polymerize in about 1 -2 hour.
Loading Buffer
The recipe for loading buffer: 95% formamide, lOmM NaOH, 0.025% Bromophenol
Blue, and 0.025% Xylene Cyanol. Gel was run in 0.6X TEB buffer. Samples were
heat-denatured at 94°C for 5 minutes and then placed on ice for 3-5 minutes. 4pl of
each sample was loaded.
Electrophoresis conditions
a). Fragment Size: 150-200bp
Run under 6 Watts for 10-12 hours at room temperature
b). Fragment Size: > 200bp
Run under 8 Watts for 10-12 hours at room temperature
Exposure
Gel was dried and exposed to autoradiographic film at room temperature for 16-18
hours.
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Table 2. "Hot" PCR recipe





Taq (5U) 0.1 pi




3. RNA manipulation and techniques
RNA is more susceptible to degradation than DNA, due to the ability of the 2'
hydroxyl groups adjacent to the phosphodiester linkages in RNA to act as
intramolecular nucleophiles in both base- and enzyme-catalyzed hydrolysis. Whereas
deoxyribonucleases (DNases) require metal ions for activity and can therefore be
inactivated with chelating agents (e.g. EDTA), many ribonucleases (RNases) bypass
the need for metal ions by taking advantage of the 2' hydroxyl group as a reactive
species. Therefore special care was taken to protect RNA from Rnases: Gloves were
always worn when working with RNA. Sterile, disposable plasticware was used.
DEPC was used to treat solutions if necessary.
65
3.1.Total RNA-isolation (TRIZOL method)
Isolation of RNA from cultured cells was performed with TRIZOL reagent (Gibco-
BRL). Culture medium was changed 2 hours before harvesting cells. Cells were
collected by trypsinizing and washing. Cells were spun down at 1200rpm in a
microfuge for 3 minute. Excess medium was removed and 1 ml Trizol reagent was
added. The tube was vortexed, inverted and left at room temperature for lOminutes
(stringy-like material should be seen). The tube was spun in a microfuge at
13000rpm for lOminutes at 4° C. Supernatant was transferred into fresh RNAse free
eppendorf tube and 200pl of chloroform was added. The tube was vortexed for 15
seconds and left at room temperature for 3 minutes. The tube was spun in a
microfuge at 13000rpm for 15 minutes at 4° C. The top layer (clear) was carefully
transferred into a new RNAse free eppendorf tube and 500pl of isopropanol was
added. The tube was inverted to mix and left for 10 minutes at room temperature.
The tube was spun in a microfuge at 13000 for 10 minutes at 4°C. (The RNA formed
a white pellet). Pellet was washed with lOOpl of 75% ethanol (made by diluting into
DEPC-treated water). The tube was spun in a microfuge at 7500xg for 5 minutes at
4°C. Supernatant was removed. Pellet was air-dried for 10 minutes. Pellet was
dissolved in 25pl of DEPC-treated water. The pellet was heated for 10 minutes at
60°C to help dissolve RNA.
3.2. mRNA-isolation (Qiagen Oligotex method)
Isolation of Poly A+ mRNA (from 5xl05 -5xl07 culture cells) was performed with
Oligotex Direct mRNA kit.
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Preparation before starting
Oligotex suspension was heated to 37°C in a water bath or heating block, mixed by
vortexing, and then placed at room temperature. A water bath or heating block was
heated to 70°C, and buffer OEB was heated to 70°C. 30pl P-Mercaptoethanol was
added to 1ml buffer OL1 in a fume hood, buffer OW1 and buffer OL1 were
redissolved by warming at 37°C, and then placed at room temperature. Cell pellets
was stored at -70°C for later use or used directly in the procedure. Unless otherwise
indicated, all protocol steps, including centrifugation, were performed at 20 to 30°C.
Unless otherwise indicated, all centrifugation steps were performed in a
microcentrifuge at maximum speed 13000rpm.
Procedure
Sample preparation for cells grown in suspension. Used less than 5xl07. The desired
numbers of cells were spun down for 5min at lOOOrpm in an RNase-free
polypropylene centrifuge tube. All supernatant was carefully removed by aspiration.
Cells were disrupted by addition of room temperature 0.6ml buffer OL1. For pelleted
cells, the cell pellet was loosened by flicking the tube. 0.6ml buffer OL1 was added.
The tube was vortexed for 5-10s or pipetted up and down to mixed thoroughly, and
proceeded at once with next step. The sample was homogenized. The lysate was
pipetted directly onto a QIAshredder spin column placed in 2ml collection tube, and
centrifuged for 2min at maximum speed. Action was taken to make sure that
homogenization is complete. 1,2ml buffer ODB was added to the lysate, and mixed
thoroughly by pipetting. The tube was centrifuged in a microcentrifuge for 3min at
maximum speed. The supernatant was transferred to a new RNase-free tube. 70ul
oligotex suspension was added to the sample, mixed thoroughly by pipetting or
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vortexing, and placed at room temperature for lOmin. The 01igotex:mRNA complex
was pelletted by centrifuging in a microcentrifuge for 5min at maximum speed
(13000rpm). The supernatant was carefully removed by pipetting. The
01igotex:mRNA pellet was resuspended thoroughly in 100 pi buffer OL1 by
vortexing or pipetting. 400pl buffer ODB was added, incubated at 70°C for 3 min
and then placed at room temperature for 10 min. The 01igotex:mRNA complex was
pelletted by centrifugation in a microcentrifuge for 5 min at 13000rpm, and the
supernatant was carefully removed by pipetting. The pellet was resuspended in 350pl
buffer OW1 by vortexing or pipetting. The sample was pipetted onto a small spin
column in a 1.5ml microifuge tube and centrifuged for 1 min at 13000rpm. The flow-
through was discarded. The spin column was transfered to a new RNase-free 1.5 ml
microfuge tube. 350pl buffer OW2 was pipetted onto the column. The column was
centrifuged for 1 min at 13000rpm, and the flow-through was discarded. Last step
was repeated once, using the same microfuge tube. The spin column was transferred
to a new RNase-free 1.5ml microfuge tube. lOOpl hot (70°C) buffer OEB was
pipetted onto the column. The resin was pipetted up and down 3 or 4 times to
resuspend, and centrifuged for 1 min at 13000rpm. To ensure maximal yield, another
lOOpl hot (70°C) buffer OEB was pipetted onto the column. The resin was pipetted
up and down 3 or 4 times to resuspend and then centrifuged for 1 min at 13000rpm.
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3.3. RT-PCR
First-strand cDNA synthesis using M-MLV RT
A 50pl reaction volume were used for 25pg total RNA or 2.5-1.25pg mRNA. The
following components were added to a nuclease-free microcentrifuge tube: 1.5pl
random hexamer (lOmg/ml), or 20pM gene-specific primer, 25pg total RNA or
1.25pg mRNA, 2.5pl lOmM dNTP Mix (lOmM each dATP, dGTP, dCTP and dTTP
at neutral pH) and sterile, distilled water to the volume of 33.5pl. The mixture was
heated to 65°C for 5min and quick chilled on ice. The contents of the tube was
collected by brief centrifugation and added: lOpl 5xFirst-Strand Buffer and 5pl 0.1M
DTT. Contents of the tube was mixed gently and incubated at 37°C for 2min. 1.5pi
(300units) ofM-MLV RT was added, and mixed by pipetting gently up and down. If
random primers were used, tube was incubated at 25°C for lOmin. The tube was
incubated lhour at 37°C. The reaction was inactivated by heating at 95°C for 15min.
The cDNA was stored at 4°C as a template for amplification in PCR.
PCR Reaction
10-20% of the first-strand reaction (5-10pl of the reaction from the previous page)
was used for PCR. PCR was performed under normal condition. If necessary, the
PCR condition was optimised.
3.4. Northern blot analysis
The procedure was divided into three sections:
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a). Electrophoresis of an RNA sample under denaturing conditions in an agarose-
formaldehyde gel.
b). Transfer of the RNA from the gel to a nitrocellulose membrane by upward
capillary transfer.




Following reagents were added: 1.5g agarose, 15ml lOxMOPS and 109.5ml ddH20.
The mixture was boiled to dissolve agarose, and cooled to 60°C. Then 25.5ml 38%
formaldehyde was added. The gel was mixed and cast.
Prepare running buffer (1000ml)
100ml lOxMOPS, 52.6ml 38% formaldehyde, and 847.4ml H20 were added and
mixed.
Prepare RNA sample buffer (lOOOpl)
lOOpl lOxMOPS, 500pl formamide, 180pl 38% formaldehyde, 216pl ddH20, and
4pl ethidium bromide were added and mixed. The solution was stored at 4°C. 12pl
RNA sample buffer was used for each RNA sample.
Prepare dye (1ml)
500pl glycerol, 2.5mg xylene cyanol, 2.5mg bromophenol blue,
2 pi 0.5M EDTA and ddH20 to the volume of 1ml were added and mixed. Loading
buffer was stored at 4°C. 3pi loading buffer was used for each RNA sample.
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Run gel
The gel was run in lx running buffer at 150 volt for 3 hours, at 4°C.
2.4.2.Transfer of RNA from gel to membrane
Prepare gel for transfer
The gel was placed in a clean dish, rinsed and soaked with ddHhO for 2 15 min.
Transfer RNA from gel to membrane
A glass dish was filled with enough lOxSSC. 3 pieces ofWhatman 1MM paper was
cut, placed on the glass plate and wetted with lOxSSC. The gel was placed on the
filter paper and air bubble was squeezed out by rolling a glass pipe. A used film was
cut into suitable shape and placed over the edges of the gel to prevent the solution
bypassing the gel. A piece of nitrocellulose membrane was cut just large enough to
cover the gel and wetted in water. The wetted membrane was placed on the surface
of the gel. Action was taken to avoid getting air bubbles under the membrane. The
surface of the membrane was flooded with lOxSSC. 5 sheets of whatman 3MM
paper were cut to the same size as membrane and placed on top of the membrane.
Paper towels were put on top of the whatman 3MM paper to a height of ~6cm and a
weight was added to hold everything in place. The transferring set was left overnight.
Prepare membrane for hybridisation
paper towels and filter papers were removed and the membrane and flattened gel
were recovered. A mark was made by pencil to label the position of the wells on the
membrane and ensure that the up-down and back-front orientation were
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recognizable. The membrane was rinsed with 5xSSC, then placed on a sheet of
Whatman 3MM paper and allowed to air dry. The membrane was placed RNA-side-




The probe was labeled with Radprimer DNA labelling system (Invitrogen). 25ng
DNA dissolved in 5-20pl of sterile distilled water or TE was denatured in a
microcentrifuge tube by heating for 5min in a boiling water bath; then
immediately cooled on ice. The following additions were performed on ice: 1 ju.1
500pM dATP, lpl 500pM dGTP, lpl 500pM dTTP, 20pl 2.5x Random Primers
Solution 5pl (approximately 50pCi) [a-32P]dCTP (3000Ci/mmol, lOmCi/ml)
and dd Water to a total volume of 49pl. The tube was mixed briefly. Then lpl
Klenow fragment was added. The tube was mixed gently but thoroughly and
centrifuged 15-30s. The tube was incubated at 37°C for 10-60min. And then 5pl
Stop buffer was added to finish the reaction.
Hybridisation
Hybridisation was performed with ExpressHyb™ Hybridisation Solution (Clontech).
ExpressHyb Solution was heated to 68°C, and stirred well to completely dissolve any
precipitate. Membrane was prehybridized in a minimum of 5 ml of ExpressHyb
Solution, with continuous rotation for 30 min at 68°C in a hybridisation oven. The
marked side of the membrane was flush against the side of the bottle. Bubbles
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between the membrane and the bottle were ruled out as they could prevent
hybridisation to those areas. Radioactively labeled probe was denatured at 95-100°C
for 2-5 min, then chilled quickly on ice. Radiolabeled probe was added to 5 ml of
fresh ExpressHyb, and mixed thoroughly. The ExpressHyb Solution was replaced
with the fresh solution containing the radiolabeled probe. All air bubbles were
removed from the container, and ExpressHyb Solution was made evenly distributed
over the membrane. The hybridisation was incubated with continuous shaking for 1
hr at 68°C. The membrane was rinsed in wash solution 1 (2x SSC, 0.05% SDS)
several times at room temperature and washed for 30-40 min with continuous
agitation; the wash solution was replaced several times. The membrane was washed
two times in wash solution 2 (O.lx SSC, 0.1% SDS) with continuous shaking for 40
min at 50°C. The membrane was removed with forceps and shook off excess wash
solution. Even partially dry was prevented as allowing the membrane to dry could
cause high background and would make subsequent probe removal difficult. The
membrane was immediately covered with plastic wrap, mounted on Whatman 3 MM
chromatography paper and wrapped again with plastic wrap.
Autoradiography
Blot was exposed at -80 °C using Kodak XAR film and x-ray intensifying screens.
Strip probe from the membrane
100ml sterile H20 containing 0.5% SDS was heated to 90-100°C. Plastic wrap was
removed from membrane and immediately placed in the heated solution. The
exposure to air was reduced as less as possible.
The membrane was incubated for 10 min, shaking frequently. The hot solution was
left to cool for 10 min. The membrane was removed and air-dried until it was dry
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enough to be slipped into a plastic bag. The membrane was stored at -20°C until next
hybridisation.
4. Materials
4.1. General laboratory reagents and suppliers
Amersham Life Science UK Ltd.: Hybond-N nylon membrane
BDH Ltd.: dimethyldichlorosilane, hydrochloric, and xylene cyanol
Boehringer Mannheim UK Ltd.: proteinase K.
Difco Laboratories: agar, bacto-tryptone
Fisher Scientific UK Ltd.: 3M blotting paper, EDTA, isopropanol, sodium acetate,
sodium chloride, sodium hydroxide
Gibco BRL Life Technologies Ltd.: lOObp DNA marker ladder, agarose,
Formamide, phenol, Tris, low melting point agarose, urea.
Millipore (UK) Ltd.: disposable sterile filters.
New England Biolabs (UK) Ltd.: restrict enzyme
Promega (UK) Ltd.: oligo dT
Qiagen Ltd.: plasmid preparation kit series
Scotlab Ltd.: acrylamide/bis-acrylamide solutions
Sigma-Aldrich Company Ltd.: bromophenol blue, DTT, ethidium bromide,
formaldehyde, glycerol, IPTG, mineral oil, MOPS, parafilm M, X-gal and Fully
methylated DNA (methylation status was confirmed by bisulfite sequencing)
Strategene. Ltd.: Foetal and adult colon RNA, Foetal and adult lung RNA
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4.2. Bacterial strains used in this study
Invitrogen Life technologies Ltd.: One Shot Top 10 competent cells
4.3. Plasmid
Promega Ltd.: PGEM-T
4.4. DNA/RNA modifying enzymes
Boehringer Mannheim UK Ltd.: Klenow polymerase, restriction endonucleases
Gibco BRL Life Technologies Ltd.: restriction endonucleases,
T4 DNA kinase, Taq DNA polymerase
New England Biolabs (UK) Ltd.: restriction endonucleases, T4 DNA ligase
4.5. Radioactive reagents
Amersham International pic. : Redivue [a-32P]-dCTP (~3000Ci/mmole, lOmCi/ml),
Redivue [a-33P]-ddNTPs (4x25pl, 450pCi/ml), dATP [a-33P](3000 Ci/mmol).
4.6. Mammalian cell culture reagents
Becton Dickinson Labware: plasticware.
Difco Laboratories: trypsin
Gibco BRL Life Technologies Ltd.: RPMI1640 medium
Sigma-Aldrich Company Ltd.: P-mercaptoethanol.
75
4.7. Cancer cell lines
Cancer cell lines (see table 3) were obtained from ECACC (the European Collection
of Cell Cultures/ATCC).







lung small cell (SCLC)
non-small cell (NSCLC)
NCI-H69, -H524, -H740,
-HI672, -HI092, -HI 184,
-HI838, COR-L24, -L47,
-L51, -L88, -L279, -L311
NCI-H358, -H835, -H920, -
HI648, -H2122,
COR-L23,-L105
4.8. General solutions and buffers
PBS (lx in 500 mis): added 4.09 g NaCl, 0.093g KC1,
2.028 g Na2HP04 (7 H20) and 0.109g KH2P04 pH 7.2
lxTE : lOmM Tris-HCl, ImM EDTA, pH 8.0
1 M Tris-Cl (500 ml): added Tris base 60.5 g, adjusted pH with
concentrated HC1 and then add double distilled water to 400 ml.
20x SSC (2L pH 7.0): added NaCl 350.6 g and Na3Citrate 176.6g, then Mix and
adjusted pH to 7.0 with HC1.
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lOx TBE Buffer (4L, pH 8): added Tris-Base 432 g, Boric acid 220g,and Na2EDTA
37.2 g, Then mix and store at room temperature.
50x TAE Buffer (50x, pH 8): added Tris Base 242 g, acetic acid
57 ml and Na2EDTA 37g. Then mix and store at room temperature.














5' -ACTGCTGGGGGA GTGGA 5' -GCTGCACGTGGGTGATG A
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5'-TGTGGTCCTCACCTATGCCT 5'-ATG GCACC GGCCGATT
SMOcDNA
365bp






























2. Mutational analysis by SSCP and sequencing 86
3. Analysis of methylation of the promoter CpG island 87




MBD3 is a member of the methyl-CpG-binding domain (MBD) protein family. It is
an important subunit of the NuRD complex, a multisubunit complex containing
nucleosome remodeling and histone deacetylase activities(Wade et al., 1998; Wade
et al., 1999; Zhang Y et al., 1999). MBD3 encodes a 32 kD protein. The MBD
domain is encoded by exons 1 and 2 (see Figure 7). Like MBD2, MBD3 also
contains one of C-terminal coiled-coil (cc) domains (see Figure 8), which are
ubiquitous and highly versatile assembly motifs found in a wide range of structural
and regulatory proteins (Hendrich and Bird, 1998). Coiled-coil domains are involved
in protein-protein interactions and exhibit a broad range of different functions related
to their specific folding of coiled-coil domains. MBD3 is located on chromosome
19p 13.3, a region of Loss of Heterozygosity in both colon and lung cancers (Resta et
al., 1998; Dong et al., 1998; Trojan et al., 2000). Inactivating LKB1/STK11 germline
mutations in combination with loss of the wildtype allele by chromosomal loss or
methylation are responsible for the development of hamartomatous polyps and
adenocarcinomas in Peutz-Jeghers syndrome patients. LKB1/STK11 however is
rarely involved in sporadic colon cancer cases and at most 33% of NSCLC cases
(Resta et al., 1998; Avizienyte et al., 1998; Trojan et al., 2000; Esteller et al., 2000;
Launonen et al., 2000), leading us to consider the role of MBD3 as an alternative
tumour suppressor gene on this location. This gene is tightly linked to LKBl/STKll,
being only 500kb away on chromosome 19pl3.3(data available on the website
http://www.ncbi.nlm.nih.gov). To investigate its possible role as a tumour suppressor
gene in colon and lung carcinogenesis, we screened a set of colon and lung cancer
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2.Mutational analysis by SSCP and sequencing
PCR of genomic DNA was carried out using 6 pairs of intron primers as listed in
Table4. The primer sets covered the entire coding region (exons 1 to 6) ofMBD3 and
included splice acceptor and donor sites (see Figure 7). Seven colon cancer, 11
SCLC, 8 NSCLC, one immortalised non-tumourigenic human bronchial epithelial
cell, and 51 MSS primary CRC tumours were subjected to mutation screening.
Two aberrant SSCP bandshifts in these cell lines and primary tumour samples were
found, that were then sequenced. Both of the changes were heterozygous as seen by
the retention of normal bands in SSCP or sequencing gels and all were in cell lines.
Specifically, in exon 3 of DLD1/HCT15 (cell lines derived from the same tumour), a
G to A transition leads to a silent change (T104)(see Figure 9,10). In exon 6 of
DLD1/HCT15, a C to A transversion leads to a novel leucine to methionine
substitution at residue 248 (L248M) (see Figurell, 12). Since matching normal
tissues were not available for the cell lines to confirm somatic mutation events in
these cases, independent normal DNAs were then screened to see if these differences
exist in cells of non-cancerous individuals. The exon 3 variant was found in 1 of 47
normals indicating that it is probably a rare polymorphism, but the exon 6
substitution was not seen in 54 normals, nor the silent exon3 variant in 47 normals.
There is a possibility that the L248M change is a true cancer-related mutation
although it is a conservative substitution and so may have little functional effect.
No mutations were found in the primary colon tumours. Interestingly, the same
bandshift was found using primer pair MBD3/7 and MBD3/8 for exon3 in two
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patients, which was postulated to be a rare single-nucleotide polymorphism (SNP)
(see Figure 13) as it was also found in normal matched tissue from the same patients.
Considering the low frequency of changes in the lung cancer cell lines, it was
decided not to screen a panel of NSCLC primary samples that would have been
available.
3.Analysis of methylation of the promoter CpG island
The method used to screen for methylation concentrated on the nine Hpall/Mspl sites
in the CpG island (see Figure 14 and 15), all of which must be methylated to allow
PCR to give a positive result after Hpall digestion, and therefore gives a qualitative
(total vs. partial/no methylation) rather than quantitative assessment of methylation.
Results from the cell lines indicated an absence of total methylation (see Figure 16).
4.Expression ofMBD3 in colon and lung cancer cell lines
RT-PCR showed that MBD3 expression is detectable in all the cell lines tested (see
Figurel7 and 18). To further confirm the expression, northern hybridisation analysis
was performed. The result is consistent with that of RT-PCR (see Figure 19). Since
25ug total normal adult colon RNA was used as positive control, the band is weaker
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Figure 12 Heterozygous sequence change in exon 6 of DLD1
+C to A
A G C T
A C to A transversion was found by DNA sequencing
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Figure 13 Putative SNP in primary tumour
Lanes are: 1. patient A tumour, 2. patient A normal tissue,
3. patient B tumour and 4. patient B normal tissue.
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Figure 14 MBD3 CpG island analysed by CpGPlot
The original definition suggested by Gardiner-Garden and Frommer is a region
greater than 200 base pairs (bp) with a high-GC content and an observed/expected
ratio for the occurrence ofCpG >0.6.
For MBD3, the input sequence is AC005943 nt8000-10104.
Window size = 100
Observed/Expected ratio > 0.60
Percent C + Percent G > 50.00
Length=912 (8540-9451) > 200































The sequence Genebank accession number: AC005943 reverse-complement nt8500-
9300. There are 9 HapII/MspI recognised CpG sites in the PCR region generated by
primer pair MBD3/17 and MBD3/18. The translation start ATG is located between
sixth and seventh HapII/MspI recognised CpG sites.
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Figure 16 Methylation sensitiveHpallrestriction
followed by PCR
600bp m
1 2 3 4 5 6 7 8
600bp
9 10 11 12 13 14 15 16 17 18 19 20 21
Lanes are: 1. DNA marker, 2. totally methylated DNA,
3. HT29, 4. SW480, 5. COLO320, 6. HCT116, 7. DLD1,
8. LOVO, 9. DNA marker, 10. H69, 11. H524, 12. H740,
13. H1672, 14. COR L24, 15. COR L47, 16. COR LSI,
H358, 18. H835, 19. H920, 20. H1648 and 21. H2122.
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Lanes are: 1. DNA marker, 2. HT29, 3. SW480, 4. COLO320,
5. HCT116, 6. DLD1, 7. LOVO and 8. normal adult colon.
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Lanes are: 1. DNA marker, 2. H69, 3. H524, 4. H740, 5. H1672,
6. COR L24? 7. H358, 8. H835 and 9. H920
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Figure 19 MBD3 po!yA+ Northern hybridisation
Lane 1-6 represents HT29, SW480, COLO320, DLD1, LOVO and normal adult colon
total RNA respectively. /3-actin was included as positive control. The transcript size
ofMBD3 and /3-actin are 2.4kb and 1.8kb respectively.
Figure19MBD3polyA+Northernhybridisation 98
5.Discussion
To investigate the role of MBD3 in colon and lung tumourigenesis this gene was
assayed for mutations, promoter methylation and lack of expression. The MBD3 gene
spans more than 16kb of genomic DNA but contains 7 relatively small exons(six of
which are coding). PCR followed by SSCP is a simple, sensitive method to screen
for nucleotide substitutions in DNA. Exonl (containing the start methionine codon)
is located within a typical CpG island which stretches about lkb with observed vs
expected ratio >0.6 and 78% CG content (see Figure 19). As high CG content DNA
sequence is usually refractory to normal Taq PCR, it was necessary to use high
fidelity DNA polymerase Pfx with high concentration Enhancer solution (5x) and
high denaturation temperature to facilitate PCR amplification of this region. The
remaining 5 exons(2-6) could be amplified using standard Taq polymerase.
Two missense mutations were found (1/7 colon and 1/20 lung) cancer cell lines, and
none in colon primaries. Both mutations were located outside the MBD (methyl-
CpG-binding domain), and one appears to be a naturally occurring rare
polymorphism. The coincidence of the missense and silent mutations in
DLD1/HCT15 may simply reflect the mismatch repair defect of these cell lines due
to MSH6 mutation. The L248M change may be a somatic event, but since it is a
conservetive substitution it may not be significant for tumourigenesis. Considering
the expressions of other genes involved in tumourigenesis are silenced or reduced by
epigenetic alterations, with which hypermethylation is the most common associated
events. Hypermethylation usually shows methylation across the bulk of the
associated CpG island. We expected to find such abnormalities with MBD3.
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Hypermethylation is an alternative mechanism for inactivation of tumour suppressor
gene and tumour-related genes in many human cancers (Momparler, 2003) even in
some tumour types where mutations rarely occur (e.g. GSTP1 in prostate cancers,
Millar et al., 1999). In sporadic Colorectal cancer, methylation of MLH1 is the
predominant mechanism of inactivation rather than mutation (Cunningham et al.,
1998), while the reverse is true for inactivation in HNPCC cases (Leach et al., 1993;
Fishel et al., 1993; Aaltonen et al., 1993; Kolodner et al., 1999).
Methylation analysis using restriction enzyme digestion followed by PCR is a simple
and rapid method of methylation analysis based on the fact that some restriction
enzymes are unable to cut methylated DNA but their isoschizomers can. Hpall -
Mspl were selected as they have 9 recognition sites in the promoter region we were
looking at. Both enzymes recognize CCGG sequence; however Hpall is unable to cut
DNA if cytosine is methylated. In this study, there are nine CpG sites of the MBD3
recognised by the isoschizomers pair. If all of the nine sites are methylated, the
Hpall digested DNA will give a clear PCR band but Mspl will not. Since
hypermethylation usually occurs across the bulk of the associated CpG island, the
nine CpG sites of the MBD3 CpG island (about 50% of the putative CpG island)
were expected to be methylated in a significant proportion of cells to give a
detectable PCR result if this phenomenon had occurred. The data showed that none
of the cell lines were fully methylated across the region tested.
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In addition to epigenetic abnormality due to hypermethylation, gene silencing can
also occur in the absence ofmethylation (perhaps due to inactivation of transfactors).
Thus RT-PCR and confirming northern hybridisation analyses were performed to see
if the expression ofMBD3 is absent or reduced. RT-PCR and northern hybridisation
analyses results showed that MBD3 is expressed in all the cell lines assayed at
significant levels. These results are consistent with a lack of aberrant, tumour-
associated silencing of the gene. In conclusion, MBD3 is not a target of genetic or
epigenetic alteration in colon and lung cancer.
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Analysis of Expression and Methylation
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MBD2 is a transcriptional co-repressor (Ng et al., 1999) that binds specifically to
mCpG residues in DNA and exhibits a preference for densely methylated regions. It
is associated with HDAC1 and HDAC2. MBD2 may direct Mi-2 remodeling
complexes to methylated regions in chromatin, mediating transcriptional silencing
(Zhang et al., 1999 and Wade et al., 1999). MBD2, mapped on the human
chromosome 18q21 (a region of LOH in colon and lung cancer), comprises six
coding exons and one non-coding exon. The MBD domain is encoded within exons 1
and 2.
Prior to this study, the colon and lung cancer cell line panel had been screened for
mutations in exons 2-6, but very few changes had been found (Bader et al., 2003).
Exon 1 containing the N-terminal portion of the MBD was not studied because its
sequence is very G/C rich and so difficult to PCR amplify. Although a method was
then developed to PCR amplify across the region using Pfx polymerase and its
enhancer solution, this region was still too large for simple SSCP analysis, and no
convenient enzymes were found to cut the PCR fragments into smaller pieces before
SSCP. No other methods were developed or attempted to screen this region. Reports
have been made of a decrease in expression of MBD2 in some tumours (Muller-
Tidow et al., 2001) raising the possibility that MBD2 is inactivated not by mutation
but by downregulation. The aim of this project was therefore to look at expression of
the gene in the cell lines and to screen for hypermethylation of the putative promoter
region.
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2. MBD2 is expressed in colon and lung cancer cell lines
Northern hybridisation analysis showed that MBD2 expression is detectable in the
selection of cell lines tested (see Figure 20 and 21). By eye, the intensity ofMBD2
bands indicated that expression was abundant and roughly equivalent. P-actin was
used as a loading control to assist with comparisions. No attempt was made to
generate quantitative measurements of expression levels by densitometry or real time
PCR (as in references Billard et al., 2002 and Muller-Tidow et al., 2001). At best,
such data would simply have replicated that already published and would not address
the probable mechanism(s) involved in downregulation of the gene, e.g.
hypermethylation.
3. No dense methylation found in the promoter CpG island
The method used to screen for methylation concentrated on the two Smal/Xmal sites
within a 670bp region of the predicted CpG island (nt425-1095 of sequence
AF120988)(see figure 22 and 23). Both Smal and Xmal recognize CCCGGG
sequence. Two recognition sites of both restriction enzymes contain CpG pair(s).
When the CpG sites are methylated, Smal will not cut, but Xmal is unaffedted. Both
sites must be methylated to allow PCR and to give a positive result after Smal
digestion. The assay therefore gives a qualitative (total vs. partial/no methylation)
rather than a quantitative assessment of methylation. Xmal was used for a standard
control as it can cut methylated CpG sites. Results from the cell lines indicated an
absence of total methylation as judged by the lack of PCR. A totally methylated
genomic DNA control (Sigma) was used in parallel as positive control for the
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Figure 22 MBD2 CpG island analysed by CpGPlot
The input MBD2 exonl sequence is AF120988 ntl-1993
Window size = 100
Observed/Expected ratio > 0.60
Percent C + Percent G > 50.00
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The sequence accession number at Genebank is AF120988 (nt301-1141). There are two
Smal/Xmal restriction sites in the PCR region amplified by primer pair MBD2.15 and
MBD2.16. The translation start ATGs for both MBD2a and MBD2b locate in this region.
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Figure 24 MBD2 methylation
analysis of colon cancer cell lines
600bp- II
12345678
Lanes are: 1. DNA maker, 2. total
methylated DNA. 3. HT29, 4. SW480, 5.
COLO320, 6. HCT116, 7. DLD1 and
8. LOVO.
no
Figure 25 MBD2 methylation
analysis of lung cancer cell lines
Lanes are: 1. DNA marker, 2. total
methylated DNA, 3. H69, 4. H524, 5. H740,




The maintenance ofCpG-methylation is essential for normal embryonic development
and deletional mutants that disturb this process can be lethal (Li et al., 1992).
Promoter hypermethylation has been shown to be associated with the silencing of
tumour suppressor genes. As an important element in the process of methylation-
associated transcriptional repression, MBD2 was considered to be an attractive
candidate as tumour suppressor gene, the loss of whose activity could lead to further,
genomewide changes in gene regulation, thus contributing to tumourigenic
progression.
Northern hybridization was used to look for the absence of MBD2 expression in a
panel of human tumour cell lines and showed that it is expressed in all the cell lines
assayed. To a first approximation therefore, MBD2 is expressed at significant levels
in these colon and lung lines, but other reports describe a decrease in expression of
between 20 and 80% of some primary cancers compared with normal tissue (Muller-
Tidow C et al., 2001). One possible mechanism for such a decrease in expression
involves hypermethylation of the promoter region. Since no matching normal tissue
was available for comparison with the cell lines studied, assays were done to look for
such methylation in the tumour lines.
MBD2 contains a typical CpG island starting upstream of exonl and crossing the
intron-exon conjunction, stretching about 800bp. Restriction enzyme digestion
followed by PCR was used to assay MBD2 promoter methylation status. Smal/Xmal
were selected to assay two CpG sites within the promoter region. Reports of
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hypermethylation of other genes involved in tumourigenesis usually shows
methylation across the bulk of the associated CpG island. We would therefore have
expected the two CpG sites of the MBD2 CpG island to have been methylated in a
significant proportion of cells to give a detectable PCR result after digestion by these
enzymes that have at most 2 sites within the PCR fragment. Our result shows that
none of the cell lines were methylated at the sites tested. In combination therefore,
our expression analysis and methylation results are consistent with a lack of aberrant,
tumour-associated silencing of the gene.
The primary tumour-associated decreased in expression ofMBD2 that is reported in
the literature may still be correct, despite our lack of supporting evidence in the cell
lines. Another mechanism by which expression could be decreased may be simply
due to a lack of compensatory upregulated expression from the remaining wild type
allele after LOH of the region. There are no reports yet of methylation of the DCC
gene, suggesting that its decreased expression in colon tumours may also simply be
due to the 18q21 LOH.
On the other hand, this data is consistent with reports showing that MBD2
overexpression can occur in breast cancer (Billard et al., 2002), and that MBD2
downregulation inhibits the growth of cultured transformed cells (Slack et al., 2002).
Recently it was reported that deficiency of Mbd2 suppresses intestinal
tumourigenesis (Owen et al., 2003). In that study, APCM,n/+Mbd2~/~ mice survived
significantly longer than control mice (APCMw/+Mbd2+/+), whereas Mbd2+/~ mice
survived for an intermediate length of time. At death, Mbd'~ mice had 10 times fewer
113
adenomas than APCM,n/+Mbd2+/+controls. Taken together, it is more likely that
MBD2 acts as an oncogenic factor in tumour progression.
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Analysis of Methylation Status of PTC
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As mentioned in Chapter 1, the hedgehog pathway is important for colon and lung
development. Shh knockout mice have been reported to show foregut, trachea and
lung abnormalities, reduction of intestinal smooth muscle, gut malrotation and
annular pancreas and persistent cloaca, where the distal intestinal and genitourinary
tracts remain in a common channel. PTC normally maintains the hedgehog pathway
in an inactive state by inhibiting the signalling effector SMO (reviewed in Ingham
and McMahon, 2001). Shh activates signalling in target cells by inhibiting PTC,
resulting in derepression of SMO and activation of Hedgehog target genes such as
PTC and Glil. Whereas this pathway normally is regulated by the spatially and
temporally restricted expression of Shh, loss-of-function PTC mutations are
associated with constitutive hedgehog signalling in human cancers, particularly
BCCs (reviewed in Mullor et al.,2002). The findings of mutations in the PTC gene in
both Gorlin's syndrome and sporadic basal cell carcinomas are thus precedents for
abnormalities of this gene in human disease.
The PTC gene is located on chromosome 9q22.3 where it contains 23 exons
spanning approximately 34 kb. There are two CpG islands, the first one covering the
putative promoter region (5'-untranslated region and exonl)(see figure 26) and the
second one covering exon 2 and stretching into both intronl and intron2. In its 5'-
untranslated region, there is a seven triplet CGG repeat region (see figure 27), a
sequence that can be vulnerable to expansion and deletion in some diseases and
microsatellite unstable cancers. As a part of a study of PTC in colon and lung
cancers, a panel of cancer cell lines and primary tumours were assayed for PTC
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expression, hypermethylation of the first CpG island and instability of the CGG
repeat.
2. No cancerous mutation found in the triplet repeat sequence
4/8 colon cancer cell lines and 6/21 lung cancer cell lines presented identically
shifted bands when assayed by SSCP across the repeat region. In the colon cancer
set, all of these bandshifts occurred in MSI lines. In the lung cancer set, 4 bandshifts
occurred in SCLC cell lines, 1 in an NSCLC cell line and 1 in the immortalised non-
tumourigenic human bronchial epithelial cell. Further, MSS primary tumours with
matched normal tissue and MSI primary tumours with matched normal tissue were
also screened. Although 42/97 (42%) bandshifts were found in the MSS primary
tumours and 10/18 (56%) bandshifts in the MSI primary tumours, all of these
bandshifts also occurred in matched normal tissues. Considering the incidence in
both normal and tumour samples, and the apparent identical nature of the bandshift,
it was concluded that this is a naturally occurring polymorphism in the gene.
3. PTC is expressed in all cancer cell lines tested.
Northern hybridisation analysis (see figures 28 and 29) showed that PTC is
expressed in colon and lung cancer cell lines. The intensity of bands is almost equal
to those of normal foetal and adult colon and lung.
4. No dense methylation found in the promoter CpG island
The method used to screen for methylation concentrated on the 5 Xmal/Smal sites, 4
NotI sites, all of which must be methylated to allow PCR and give a positive result
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after Smal digestion, and therefore gives a qualitative assessment of methylation(as
described in Chapter 2). Results from the cell lines indicated an absence of total
methylation (see Figures 30, 31 and 32).
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Figure 26 PTC CpG island analysed by CpGPlot
The input sequence is NT008470 (reverse complemented, nt96957701-96959386).
Window size - 100
Observed/Expected ratio > 0.60
Percent C + Percent G > 50.00
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Figure 27 Smal/Xmal restriction CpG sites in the PCR regions
CGCG/tGCC4,47'CGCG7GGC/JGAAACCCAAGCCATCTGACAGCCCCGGGGGCGGGAGCT





























The sequence accession number at Genebank is NT008470 (reverse complemented,
nt96957701-96958922). There are 3 Smal/Xmal sites in the PCR region amplified by
PTC 1/2, 1 site in the PCR region amplified by PTC3/4 and 2 sites in the PCR region
amplified by PTC9/6. One of the translation start ATG locate in the region between
PTC9 and PTC6. The seven CGG triplets repeat locates upstream of the translation
start ATG.
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Figure 28 PTC Northern hybridisation analysis
of colon cancer cell lines
PTC
Beta-actin ......
12 3 4 5 6
Lanes are: 1. HT29, 2. SW480, 3. COLO320,









Figure30PTCmethylationanalysisofcolonndlu ga cer celllin s(PTC1/2)
600bp-
1234567890123456
Lanesr :1.DNAmarker,2tot llyethylated ,3HT294SW480
5.COLO320,6HCT1167DLD ,8L VO969,105241740 12.H1672,3.CORL24,4-LSI,5H358andl .835. 124
Figure 31 PTC methylation analysis of colon and lung






A. Lanes are: 1. DNA marker, 2. totally methylated DNA, 3. HT29,
4. SW480, 5. COLO320, 6. HCT116, 7. DLD1 and 8. LOVO
B. Lanes are: 1. DNA marker, 2. totally methylated DNA, 3. H69,
4. H524, 5. H740, 6. H1672, 7. COR L24, 8. H35S, 9. H835 and
10. H920.
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A. Lanes are: 1. DNA marker, 2. totally methylated DNA, 3. HT29,
4. SW480, 5. COLO320, 6. HCT116, 7. DLD1 and 8. LOVO.
B. Lanes are: 1. DNA marker, 2. totally methylated DNA, 3. H69,




Mutation in triplet repeat sequences can cause human diseases by forming a variety
of DNA conformations (see review by Reddy PS et al., 1997). Although the
mechanism by which trinucleotide expansion occurs is not completely understood, it
is currently thought that DNA secondary structure plays an important role in the
process. Recent studies have shown that CAG, CTG, CCG and CGG repeats form
stable secondary structures in vivo that defeat DNA repair enzymes (Morrone et al.,
1997). During replication, a structure-specific nuclease (FEN-1) is required to cleave
displaced Okazaki fragments (flaps). The presence of a hairpin formed by CNG
(where N=C or G) expansion results in stimulation of flap formation and inhibition
of FEN-1 cleavage, thus increasing the likelihood of occurrence of uncleaved flaps.
Hairpins formed by the (GCC).(CGG) expansions responsible for Fragile X
syndrome were also found to be 10-15 times more efficient substrates for
methyltransferase (the enzyme that methylates the CpG sites in DNA) than the
corresponding Watson-Crick duplexes (Chen et al., 1998). Expansion of this repeat,
which is located in the 5'-untranslated region of the Fragile X mental retardation
gene (FMR1), results in hypermethylation, formation of a CpG island within the
FMR1 promoter and reduced FMR1 transcription (reviewed in Cummings et al.,
2000). Similarly, expanded (CGG).(GCC) repeats in the promoter region of the
FMR2 gene are hypermethylated and lead to transcriptional silencing of FMR2 in
FRAXE patients (reviewed in Cummings et al., 2000). One group showed that
alteration of triplet repeat sequences may cause improper expression of disease
related genes, through their effects on chromatin structure (Tomita et al., 2003).
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They found that (CGG)i2 disrupts an array of positioned nucleosomes and insertion
of (CGG)i2 increases gene expression about 10-fold of a UAS-less promoter.
In the case of PTC, it was hypothesised that the alteration of (CGG)8 in PTC
promoter region may be associated with tumourigenesis and so mutation analysis
was performed to look for CGG expansion and deletion. The results showed that
there was one commonly occurring alteration that was not related to cancer as it also
occurred in matched normal tissues. The change was thus concluded to be a
polymorphism.
Tumour suppressor genes are often down regulated in cancer, especially by promoter
hypermethylation. PTC expression and methylation status were also studied
therefore. The results showed expression of PTC in both colon and lung cancer cell
lines and no methylation, at least not at the two Smal sites, in the promoter region,
which is consistent with the northernblot data. In addition to SSCP data screening for
mutation of PTC (from our laboratory, unpublished), there is thus no evidence to
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As mentioned in Chapter 1, the Hedgehog pathway plays an important role in
development of several tissues, including colon and lung. Studies have shown that
several members are implicated in cancers. As a key member of the hedgehog
pathway, SMO is essential for pattern formation and morphogenesis in multicellular
organisms. In the absence of Hh, PTC binds to SMO and inhibits its activity, but
when present Hh binds to PTC and stops PTC inhibition of SMO, that then transmits
a signal to a cytoplasmic complex that ultimately leads to GLI activation and
downstream gene expression. In mouse knock-out models of SMO, the phenotype
essentially mimics knock-out of Shh and includes developmental abnormalities of the
gut. Mutations have been published for Hh and PTC in medulloblastomas and basal
cell carcinomas presumably due to consitutive activation of the Hh pathway.
Oncogenic mutations have also been reported for SMO in sporadic basal cell
carcinoma. Colon and lung cancer cell lines and primary tumours have been screened
for abnormalities in SHH and PTC with very few changes identified (other
unpublished work from our laboratory and Chapter 5 for PTC). SMO is also a
reasonable candidate in the Hh pathway to screen for mutations and epigenetic
changes in the same samples.
2. SMO is down regulated in colon cancer and lung cancer cell lines.
Colon cancer and lung cancer cell lines were analysed by RT-PCR for expression
(see Figures 33 and 34). Colon cancer cell lines were further assayed by Northern
Blot analysis of polyA RNA, with total RNA from foetal and adult colon as normal
controls (see Figure 35). A PCR product amplified by primers in exon3 and
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6(SM013 and SM043 see Table4) was used as the probe. Foetal and adult colon
expressed SMO; however, 3/7 colon cancer cell lines and 6/9 lung cancer cell lines
lacked expression. Colon cancer cell lines COLO320, HCT116 and LOVO clearly
express SMO, while HT29, DLD1 and LSI 80 were negative. The results of Northern
hybridisation analysis were consistent with those of RT-PCR except that the SW480
expression is very low. In this case, there seems to be a very little expression, below
the level of detection by Northern blot hybridisation but detectable by the much more
sensitive method of PCR.In lung cancer cell lines, COR-L47, COR-L51, H358,
H2122 and COR-L23 lack expression ofSMO as detected by PCR. In contrast, COR-
L24, COR-L279, HI648, COR-L105 and the immortalised non-tumourigenic human
bronchial epithelial cell line BW1799 (a "normal" control) expressed SMO, although
expression COR-L279 appears low. Expression and lack of expression did not
correlate with lung cancer type (SCLC vs NSCLC).
3. SMO is methylated in non-expressing cancer cell lines.
Since some of the cell lines were negative for SMO expression, it was important to
assay for methylation of the promoter region. Although there are as yet no reports of
the identity of the promoter region, the gene has a typical CpG island (see Figure 36),
stretching for lkb and including part of exon 1. The CpG rich region upstream of
exonl is likely to contain part or all of the promoter. With the expectation of
methylation in some or all of the SMO-negative cell lines, it was decided to use a
more sensitive and informative assay to gauge the incidence of methyl-CpG than the
methylation-sensitive restriction enzyme/PCR assay used for MBD3 and PTC. In the
latter assay, only a limited number of CpG sites is tested. Bisulfite modification of
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DNA followed by sequencing is the gold standard with highest resolution to identify
single methylated C nucleotides. Direct sequencing or cloning of PCR products
followed by sequencing individual clones can be done (see Figure 37). Direct
sequencing is faster, but cloning can resolve issues of heterogeneity of methylation
on separate alleles. It was decided to use cloning in these experiments.
After bisulfite modification ofDNA from the colon cancer cell lines, a 200bp stretch
of the putative promoter region containing 22 CpG sites (see Figure 38), was PCR
amplified and subcloned into pGEMT for sequencing. For each cancer cell line, 10
PCR clones were sequenced. The four cell lines that did not express SMO were all
fully methylated in the amplified region (see Figures 39 and 40). The cell lines
HCT116 and LOVO appeared to have one methylated and one un-methylated allele.
In the case of LOVO, 50% of sequenced clones were totally unmethylated CpG
(suggestive of one unmethylated allele)(see Figure 39), and 50% were completely or
partially methylated CpG (suggestive of a second variably methylated allele)(see
Figure 42).
Since LOVO does express SMO as seen on the Northern blot, one might predict that
the unmethylated allele is responsible for the mRNA that is produced. Alternatively,
the methylation seen on the second allele may not be extensive enough or may not
affect the key CpG sites to inhibit expression, and so the gene continues to be
expressed from both alleles. One cannot be certain of either situation without
knowledge of independent sequence information for the two genomic alleles. Such
information however was gathered in subsequent experiments (see next section). Not
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only did the data imply that one allele was largely silent (predicted to be the partially
methylated one), but the particular distribution of methylated CpG sites implicates
what sites are the key players, and perhaps also the affected transcription factors, that
are involved in silencing of the gene. In the case of HCT116, two patterns were seen
(allowing for sampling error in the number of representative clones picked for
sequencing), one fully methylated one fully unmethylated, again implying opposing
states of the two alleles. Contrary to LOVO, one predicts for HCT116 that the
mRNA seen by Northern hybridisation certainly comes only from the unmethylated
allele.
The cell lines SW480 and COLO320 showed strange results. SW480 showed very
little expression detectable by Northern blot hybridisation, but was apparently almost
entirely unmethylated. The interpretation is that although SMO of SW480 is not
methylated, the gene is kept almost silent by the activity of inhibitory transcriptional
regulators. Silencing of genes in cancers by other mechanisms beside
hypermethylation has been seen in several cases. For example, heterogeneous
methylation of some genes has been reported for genes like Rb in retinoblastoma
tumours (Stirzaker et al., 1997), pi5 in leukaemia (Melki et al., 1999), where
regardless of the extent ofmethylation, the gene appears to be silenced in the tumour.
Similarly, BRCA1 expression is low or absent in most ductal carcinomas and cell
lines (Thompson et al., 1995), while methylation occurs in only about 20% of
patients and much less frequently in cell lines (Dobrovic and Simpfendorfer 1997;
Bianco et al., 2000; Catteau et al., 1999; Esteller et al., 2000; Rice et al., 1998).
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Likewise, some leukaemias have little or no methylation of the E-cadherin promoter
yet lack expression of that gene (Melki et al., 2000).
In contrast, COLO320 showed comparatively high expression of SMO by Northern
blot hybridisation yet had total methylation across the region screened in 9 out of 10
clones sequenced. The almost total methylation could simply be due to incomplete
bisulfite modification of DNA before PCR amplification, but this is not likely
because a) the experiment was repeated and produced the same results, and b) the
PCR primers do not work on unmodified DNA as they span non-CpG cytosines that
will always be changed following bisulfite treatment thus inhibiting primer annealing
(data not shown). Allowing for sampling error of clones picked for sequencing, the
interpretation of results is that one allele ofCOLO320 is methylated (and presumably
silenced) but the other allele remains unmethylated from which a high level of
expression is generated. The lung cancer cell line COR-L51 appeared fully
methylated, however the immortalised non-tumourigenic human bronchial epithelial
cell BW1799 was completely unmethylated. These results are consistent with the
observations of expression by cDNA PCR.
4. SMO mutation occurred in the expressed allele of hemi-
methylated cell lines.
A heterozygous base substitution in exon 6 of SMO in HCT116 (G to A) was
identified during other work of the laboratory (unpublished data) and that was not
seen in 40 independent normal blood samples. This substitution was thus considered
to be a candidate mutation (in the absence of normal tissue to confirm somatic
aetiology). This base change was used to study the expressed message of SMO in
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HCT116 to identify the allelic expression of the gene in the light of the hemi-
methylated data. Primers SM021 and SM052 were used to amplify cDNA from this
cell line and others normal for this exon and run on an SSCP gel. The results showed
a bandshift for HCT116 without the normal pattern suggesting that only the mutant
was expressed (see Figure 43).
Similarly, it was interesting to clarify the expression of alleles in LOVO
(unpublished group data). Again, a heterozygous candidate mutation was found in
exon 1 for this cell line: an insertion of two CTG trinucleotides in a stretch of seven
CTGs, presumably due to the microsatellite instability of LOVO. Primers SMOl and
SM02 were used to amplify cDNA from this cell line as for the exon 6 change in
HCT116 and run on an SSCP gel. The results showed again a bandshift for LOVO,
with a very low intensity of the normal pattern, suggesting that the mutant allele was
the one expressed predominantly.
To confirm these findings, cDNA from HCT116 and LOVO was amplified again and
the products were cloned and sequenced. 10/10 clones in HCT116 had the mutant
allele. 2/8 clones in LOVO (unpublished group data)had the wild-type allele (coding
for 7 leucines in the signal peptide), while the remaining 6 clones had 9 leucines,
indicative of the mutant allele. These results suggested that SMO is preferentially
expressed from the unmethylated mutant HCT116 allele, and that LOVO has one
allele that is similarly unmethylated allowing normal expression carrying a mutation,
while the other allele that is wild type but partially methylated is almost completely
suppressed.
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Figure 33 The RT-PCR analysis of SMO in
colon cancer cell lines
600bp
123456789
Lanes are: 1. DNA marker, 2. HT29, 3. SW480,
4. COLO320, 5. HCT116, 6. DLD1, 7. LOVO,
8. LS180 and 9. normal adult colon.
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Figure 34 The RT-PCR of SMO in lung cancer cell lines
Lanes are: 1. DNAmarker, 2. COR-L47, 3. COR-L51,
4. COR L24, 5. COR-L279, 6. H164S, 7. H358, 8. H2122,








Figure 36 SMO CpG island CpGPIot analysis
The input sequence is NT007659 (nt 1-1685).
Window size = 100
Observed/Expected ratio > 0.60
Percent C + Percent G > 50.00
Length 1068 (154-1221), Length > 200
Figure36SMOCpGislandpGPlotanalysis ObservedvsExp ct
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Figure 37 Bisulfite sequencing procedure
gDNA
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G A 1 C
▼
G A T T
Taq takes ,,UM as "I"
pGEM-T Cloning
G A T C G A T C
After bisulfite modification, all of the unmethylated C are changed to U. When being
PCR amplified, those Us was taken as T by Taq. Thus, after being sequenced,
unmethylated Cs are replaced by Ts while methylated Cs remain C.
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There are 23 CpG sites in the bisulfite sequenced region by SMObis3 and SMObis4.
CpG sites and translation start site ATG are in bold. Primer sequences are in bold
and underlined.
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Figure 39 Methylation map of individual clone (1)
• Methylated C o Unmethylated C
HT29 SW480
1 •••••••••••••••••••••• 1 oooooooooooooooooooooo
2 •••••••••••••••••••••• 2 oooooooooooooooooooooo
3 •••••••••••••••••••••• 3 oooooooooooooooooooooo
4 •••••••••••••••••••••• 4 •o#*»»»#oooooooooooooo
5 5 oooooooooooooooooooooo
6 •••••••••••••••••••••• 6 •o«»«mooooooooooooooo
7 7 oooooooooooooooooooooo
8 •••••••••••••••••••••• 8 oooooooooooooooooooooo
9 •••••••••••••••••••••• 9 oooooooooooooooooooooo
10 •••••••••••••••••••••• 10 oooooooooooooooooooooo
COLO320 DLD1
1 •••••••••••••••••••••• 1 ••••••••••••••••••••••
2 •••••••••••••••••••••• 2 ••••••••••••••••••••••
3 •••••••••••••••••••••• 3 ••••••••••••••••••••••




8 oooooooooooooooooooooo 8 ••••••••••••••••••••••
9 •••••••••••••••••••••• 9 ••••••••••••••••••••••
10 •••••••••••••••••••••• 10 ••••••••••••••••••••••
HCT116 LOVO
1 •••••••••••••••••••••• 1 oooooooooooooooooooooo
2 •••••••••••••••••••••• 2 oooooooooooooooooooooo
3 3 oooooooooooooooooooooo
4 oooooooooooooooooooooo 4 oooooooooooooooooooooo
5 oooooooooooooooooooooo 5 ••••••••••••••••••••••
6 ••••••••••••••••••*••• 6 »o»»#»oo*ooooo»oo»«»»«
7 •••••••••••••••••••••• 7 •o*»»»oo#oo»o»»oo»»»»»
8 •••••••••••••••••••••• 8 oooooooooooooooooooooo
9 •••••••••••••••••••••• 9 •o»m»oo»ooooo»oo»»»»»
10 •••••••••••••••••••••• 10 (otttttotooooo********
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Figure 39 Methylation map of individual clone (2)























For every cell line, PCR product after bisulfite modification was cloned.
Ten clones were subjected to sequencing. Twenty-two CpG sites were
examined to observe their methylation status.
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Figure 40 Fully methylated sequence in the SMO CpG
island ofDLD1
C T A G
Methylated C
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Figure 41 No methylated C found in the SMO CpG island
of some SW480 cells.
No Methylated C
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Figure 42 Partially methylated sequence in the
promoter of SMO in some SW480 cells
C T A G
Methylated C
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Figure 43 SMO SSCP analysis of IICT116




Lanes are: 1. SW480, 2. HCT116 and 3. LOVO
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5. SMO and GLI3 show co-ordinated expression in colon cancer cell
lines.
As part of a study of the expression of many of the genes in the canonical Hh
pathway, colon cancer cell lines were analysed by Northern hybridisation analysis
for expression of GLI3 (see Figure 44). A 615bp PCR product amplified by primers
(Gli5 and Gli6 see Table 4) in exons 12 and 14 was used as the probe. Expression of
this gene was not found to be uniform for the set of cell lines used. Taking the
results of SMO and GLI3 expression analyses together (see Figure 45), it was found
that cell lines HT29, DLD1 and LSI80 lacked expression of both SMO and GLI3.
HCT116 and LOVO expressed SMO although this was mutated in each case, but not
GLI3. Expression of both SMO and GLI3 in normal adult colon was low but this
RNA was derived from whole tissue, a mix of cell types that may include some/many
that do not express these genes at all thus reducing the relative signal strength.




12345678 Lanesr :1.HT29,2SW4803.COLO32 ,4HC 116,5.D D ,6L VO
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Figure 45 Diagram of the expression status of














Screening of SMO in colon cancer cell lines has revealed a low frequency of
mutations (unpublished group data). However, analysis of expression in these cell
lines and in lung cancer cell lines as described here, has found that downregulation of
SMO is a common phenomenon, and that in the two colon cell lines with
heterozygous mutations, it is the mutant allele that is solely or predominantly
expressed. The mechanism of silencing of the normal gene (whether mono- or bi-
allelic) appears to be via epigenetic methylation of the promoter region. These data
are the first demonstration of loss ofSMO expression associated with tumours.
A simple model generally accepted is that PTC inhibits SMO by a direct, stable,
physical interaction, and Hh binding to PTC causes a conformational change in this
PTC-SMO receptor complex which releases SMO from inhibition. Whereas this
pathway normally is regulated by the spatially and temporally restricted expression
of Shh, loss of function PTC mutations are associated with human cancers,
particularly BCCs (Wicking et al., 1997; Gillies S et al., 1997; Gailani MR et al,
1996). In addition, activating mutations in SMO, making SMO protein resistant to the
inhibition of PTC, have been identified in BCC tumours that do not contain
detectable alterations in PTC (Lam et al., 1999; Reifenberger et al., 1998). But the
model of PTC-SMO receptor complex has been facing increasing arguments as a
number of studies are presenting different explanations for the mechanism of the
hedgehog pathway. For example, some studies show that SMO protein is not present
in a complex bound to PTC and suggest that in the absence of Hh, PTC indirectly
modifies SMO protein to generate an inactive moiety, in a non-stochiometric
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reaction (reviewed in Kalderon, 2000). Also SMO does not appear to play its role in
tumourigenesis as it was described in BCCs before. One group reported that PTC and
SMO mRNA levels have an inverse correlation with histological malignancy in
astrocytic tumours and suggest that these gene products are implicated in the
suppression of astrocytic tumours (Katayam et al., 2002). Another study showed that
the expression of an activated SMO mutant in keratinocytes is not sufficient for the
development and maintenance of BCCs (Grachtchouk et al., 2003).
The results reported here suggested that the down regulation of SMO is a common
phenomenon in colon and lung cancer cell lines and that SMO may also be able to act
as a tumour suppressor gene. Consistent with this idea is the observation that in cell
lines HCT116 and LOVO, the one allele that remains ummethylated and is expressed
is mutant while the wild-type allele is methylated and totally or almost totally
silenced. The dual role of SMO as an oncogene and as a tumour suppressor gene has
precedent. For example, p53 suffers mutations and deletions in many tumours, but
some these mutations lead to a loss of function typical for a tumour suppressor gene
while others lead to a gain of function according to an oncogene (Zalcenstein et al.,
2003). The data reported here is however the first example of phenomena specifically
relating to SMO as a tumour suppressor gene, and in a tissue type different from
earlier associations with the gene.
In recent months reports have been published of an activation of the Hh pathway in
SCLC cell lines and those of upper parts of the digestive tract (Watkins et al., 2003;
Berman et al., 2003). In each of these reports, activity of the pathway was indicated
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by expression of the ligand Shh and its downstream gene transcription activator
GLI1, and the implication was that tumourigenesis was promoted due to the
stimulatory activity of the pathway initiated by SHH expression. This was supported
by data showing that the SMO-antagonist cyclopamine inhibited growth of several
SCLC, oesophageal, gastric, biliary and pancreatic cell lines in vitro and in vivo.
Colon cancer cell lines were presented as exceptions to this trend however, especially
in the paper by Berman et al. There they showed by cDNA PCR that although the
cell lines expressed Hh ligands, many did not express GLI1 and none expressed PTC.
Curiously, data presented here (Chapter 5) shows exactly the opposite regarding
PTC. Furthermore, cDNA PCR data from our group also shows expression of GLI1
(data not shown), and for both genes several of the cell lines tested were used by
Berman et al. (DLD1, HCT116, HT29, LOVO). A simple explanation for the
difference in results would be merely technical problems of the other group since the
positive results here were reproducible and appropriate negative PCR blank controls
were used to rule out contamination artifacts. Further equivocal results were also
observed when the supplementary table from Watkins et al. was compared with the
data from Berman et al. The cDNA PCR data (the latter paper) frequently showed
positive results for SHH and GLI1 that were scored as negative cell lines in the
former paper where the assay done was Western analysis. It could be explained that
the two assays may apparently conflict in this way if the more sensitive cDNA PCR
detects gene expression that the Western cannot show. Yet Watkins et al. were able
adequately to detect the proteins in other cell lines. Most interesting was their
observation that cyclopamine could not inhibit growth or reporter gene activity in
HCT116 (Watkins and Berman papers) and DLD1 (Berman) colon cancer cell lines.
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It was shown here by cDNA PCR and Northern analyses that DLD1 is refractory to
cyclopamine because it does not express SMO whose protein product can therefore
not be inhibited. In the case of HCT116, although it expresses SMO it was found to
carry a mis-sense mutation of a conserved residue of mouse and human SMO and
related WNT receptor Frizzled. Sequence and single stranded conformation
polymorphism analyses of cDNA from HCT116 also indicated that the wild type
allele was not expressed implying that only protein carrying the putative mutation
was present. Since Berman et al. showed that HCT116, like DLD1, was refractile to
cyclopamine this mutation may alter SMO conformation enough to escape inhibition
by this drug and may also cause the expressed SMO protein to lose normal function.
Thus, colon is similar to other parts of the digestive tract as shown by Berman et al.,
in that several genes along the Hh pathway are expressed suggesting the requirement
for Hh ligand stimulation for tumour growth. However, as it is described above a
significant proportion of tumour cell lines from this tissue do not express wild type
SMO. Thus, despite expression of Hh ligand, the Hh pathway may actually be
dysfunctional or underactive during tumourigenesis of colon due to absence of SMO,
akin to tumour suppressor gene function for this gene. Alternatively, a combination
of Hh ligand expression coupled with loss of SMO may drive the unregulated Hh
signal down another pathway whose effects are tumourigenic. The fact that five of
the lung cancer cell lines also lacked SMO expression also raises the possibility that
similar changes may be occurring in lung cancer, and that the hypothesis of
canonical Hh pathway activation in relationship to lung tumourigenesis may need to
be re-examined.
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Cancer cell lines are commonly used in cancer research, including studies designed
to assess methylation abnormality. Studies have revealed that methylation is very
common in colon cancer cell lines (Suter et al., 2003) a phenomenon whose
significance remains somewhat controversial. On the one hand, it was reported that
most of the methylation of genes seen in cancer cell lines is present also in the
primary carcinomas from which they are derived (Ueki et al., 2001). On the other
hand, methylation at most loci was observed at a significantly greater frequency than
that expected from in vivo studies (Hawkins et al., 2002). The reason for the
excessive levels ofmethylation in colon cancer cell lines as opposed to their primary
counterparts is unclear, but it suggests that colon cancer cell lines may be only
representative of a small subset of real tumours, and this should be taken into account
in the use of colon cancer cell lines for epigenetic studies. Thus it suggests that
further methylation studies of primary colon and lung tumours is needed to
comprehensively assess methylation status in vivo. Of course, such experiments will
have attendant problems of mixed tumour (methylated) and normal (unmethylated)
cells that would have to be overcome or borne in mind when analysing data.
Genes silenced by DNA methylation can be reactivated by treatment with 5-aza-2-
deoxycytidine (5-Aza-dC), which is a well-established inhibitor of DNA
methyltransferase (Jones and Taylor, 1980). Inactive chromatin mediated by histone
deacetylation by HDAC is also known to be involved in gene silencing, affecting for
example p21Wafl, hTERT, and hLHR (Sowa et al., 1997; Takakura et al., 2001;
Zhang and Dufau, 2002). Trichostatin A (TSA), a histone deacetylase inhibitor, is
reported to activate genes whose expression is silenced by such HDAC activity (Van
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Lint et al., 1996). Furthermore studies show that 5-Aza-dC and TSA can
synergistically reactivate methylation-associated silenced genes (Cameron et al.,
1999). Thus, 5-Aza-dC and/or TSA should be used with the cell lines shown here to
be silent and methylated for SMO to confirm the methylation effect in further
experiments.
The other very interesting finding in the described experiments is that the lack of
expression of normal SMO (either with or without expression of mutant SMO) is
accompanied by absence of GLI3, independent of transcription of SHH, PTC, GLI1
and GLI2. These results suggest that expression of wild type SMO is required for
expression of GLI3 in the first instance but also that regulation of GLI3 by SMO can
occur independent of intervening genes of the pathway according to current dogma.
The GLI proteins are large transcription factors of >1000 amino acids that bind DNA
in a sequence-specific manner (Kinzler and Vogelstein, 1990; Vortkamp et al.,
1995), via the last three fingers of their five zinc-finger domain (Pavletich et al.,
1993). At least three forms of Ci have been shown or predicted to exist: a
cytoplasmic protein, a nuclear repressor and a nuclear activator (Aza-Blanc et al.,
1997; Ohlmeyer and Kalderon.1998; Methot and Baslerl999). C-terminally
truncated forms existing in the nucleus have dominant negative activity over that of
full length proteins and, additionally, C-terminally truncated GLI3 can act as a
transcriptional repressor (Dai et al., 1999; Ruiz 1999; Shin et al., 1999). In the
absence of SHH, GLI3 is proteolytically cleaved to the repressor (Wang et al., 2000)
that then inhibits SHH (Masuya et al., 1995) and GLI dependent transcription (Wang
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et al., 2000), reinforcing the latent state of the signalling pathway when SHH is not
present. Consistent with the observation in this report of regulation of GLI3 outwith
the canonical SHH pathway is the observation that during vertebrate limb bud
development, GLI3 restricts expression of the transcription factor dHAND before
SHH signalling is activated (Welscher et al., 2002), indicating that GLI3 can
function independent of Hh signalling, as well as being a component of the pathway.
Interestingly, during somite formation in the chick embryo, GLI3 is subject to P-
catenin mediated regulation by Wnt (Borycki et al., 2000). The Wnt/p-catenin/APC
signalling pathway is dysregulated in the majority of colon cancers (reviewed in
Giles et al., 2003), supporting the idea that dysregulation of the Hh pathway (in this
case by silencing of SMO-GLI3) may play a role in such tumours. Hh signalling is a
well documented initiator of proliferation in many vertebrate systems, including the
epithelium of the mouse gut (Ramalho-Santos et al., 2000). According to current
hypotheses, aberrant expression of SHH, loss of function of PTC, or oncogenic
mutation of SMO leading to hyperproliferation (through loss of GLI3 repression of
transcription) may have serious implications for tumour progression in the gut. The
data presented here for loss of expression ofSMO and GLI3 suggest further currently
unknown functions of these genes that act in a contradictory manner.
There was one exception to the stated trend connecting SMO to GLI3 in the cell line
panel used in these experiments, that of SW480. In this case, SMO is expressed at
very low levels only detectable by PCR while GLI3 is expressed at significant levels,
suggesting some other mechanism of activation of GLI3. If, according to the new
hypothesis proposed here that loss of function of GLI3, caused by loss of activity of
SMO, could play a role in tumourigenesis as for a tumour suppressor gene, then it
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would be of interest to ascertain the status of CL/3-expressing cell lines. Perhaps





1) MBD3. Few changes were found in a screen for mutations. Expression of the
gene remained significant and there was no complete methylation of the
putative promoter region. It was concluded that this gene plays little or no
role in colon or lung carcinogenesis.
2) MBD2. Expression of the gene remained significant and there was no
complete methylation of the putative promoter region. The data were
consistent with one of the current hypotheses regarding MBD2 that states that
continued expression of the gene is required for tumourigenesis. An attempt
was made to find a way to screen exon 1 for mutations as this was not done in
an earlier study and the exon encodes half of the methyl-CpG binding
domain. However, a suitable, reproducible method was not identified during
the time available, and screening of this exon remains to be done.
3) PTC. The CGG repeat seen in exon 1 of this gene was found to represent a
naturally occurring repeat length polymorphism that was stable even in
microsatellite unstable colon tumours. Similarly, expression of the gene
appeared normal in the cancer cell lines tested, with no complete methylation
of promoter sequences. These data show no evidence that silencing of this
gene plays a significant role in colon or lung tumourigenesis.
4) SMO/GLI3. Expression ofSMO was found to be absent, significantly reduced
or from an allele carrying a putative mutation, in a large proportion of colon
and lung cancer cell lines. Silencing of wild type alleles was accompanied by
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methylation of putative promoter sequences. Such changes suggested a
tumour suppressor role of SMO in these cancers and were the first such
observations for this gene. In order to rule out the possibility that these
changes were simply an artifact of transformation of cells in culture, primary
tumour samples need to be assayed. Furthermore, the role of methylation in
the silencing of SMO should be tested by treatment of appropriate cell lines
with the methylation-reversing drug 5azaC and/or the histone deacetylase
inhibitor trichostatin A.
Absence of expression of GLI3 was also observed in association with loss of
SMO or expression of only SMO message containing a putative mutation,
independent of the other genes of the Hh pathway tested in this study. There
are two main implications of these results. Firstly, that GLI3 is regulated by
SMO in a manner outside the normal sequence of steps currently thought to
comprise the Hh pathway. Loss of GLI3 expression may be due either to
absence of SMO-related activation or may also be mediated by tumour-
associated methylation and silencing of its promoter. The promoter sequence
of GLI3 should therefore be tested for methylation, and re-expression could
be tested with 5azaC and/or TSA. Experiments should also be done to try to
demonstrate re-expression of GLI3 in association with re-expression of SMO,
for example by transfection of a SMO cDNA expression construct. Secondly
that GLI3 may also have a role in tumourigenesis as the effector gene
regulated by SMO and/or as a tumour suppressor gene function in its own
right. If the latter is true, one might expect the cases where SMO is absent or
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present (LOVO or COLO320) but GLI3 still expressed to have a mutation in
GLI3. Therefore it would be interesting to screen those cell lines for
mutations, as well as a set ofprimary tumours.
The possible activity of SMO and Gli3 as a tumour suppressor can be
examined by a tumourigenesis assay in nude mice. For example, FIT29 and
exogenous SMO transfected HT29 can be transplanted into nude mice to
assay tumour growth rate. Also Smo and GH3 targeted disruption mice can be
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